Type 2 Diabetes Exacerbates Bone Loss in Native American Women by Leyva, Misti J.
   TYPE 2 DIABETES EXACERBATES BONE LOSS IN 
NATIVE AMERICAN WOMEN 
 
 
   By 
      MISTI J. LEYVA 
   Bachelor of Arts in Psychology  
   Texas Tech University 
   Lubbock, Texas 
   1990 
 
   Master of Science in Nutritional Sciences  
   University of Oklahoma Health Sciences Center 
   Oklahoma City, Oklahoma 
   2001 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   DOCTOR OF PHILOSOPHY 
   May, 2012  
ii 
 
   TYPE 2 DIABETES EXACERBATES BONE LOSS IN 
NATIVE AMERICAN WOMEN 
 
 
   Dissertation Approved: 
 
   Dr. Brenda J. Smith 
  Dissertation Adviser 
   Dr. Nancy Betts 
 
   Dr. Janice Hermann 
 
   Dr. Christine Johnson 
  Outside Committee Member 
  Dr. Sheryl A. Tucker 
   Dean of the Graduate College 
iii 
 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ......................................................................................................1 
 
 Background ..............................................................................................................1 
 Problem Statement ...................................................................................................4 
 Purpose .....................................................................................................................4 
 Hypotheses and Specific Aims ................................................................................4 
 Limitations ...............................................................................................................6 
 Delimitations ............................................................................................................6 
  
 
 
II. REVIEW OF LITERATURE....................................................................................7 
  
 Bone Tissue ..............................................................................................................7 
 Osteoporosis Defined ...............................................................................................8 
 Risk Factors for Osteoporosis ..................................................................................9 
 Obesity and Type 2 Diabetes .................................................................................15 
 Obesity and Bone Health .......................................................................................19 
 Type 2 Diabetes and Bone Integrity ......................................................................23 
 Factors Affecting Bone Strength ...........................................................................24 
 Type 2 Diabetes and Bone Metabolism .................................................................27 
 Native Americans and Osteoporosis Risk ..............................................................29 
 
 
III. METHODOLOGY ................................................................................................32 
 
 Research Design.....................................................................................................32 
 Data Collection ......................................................................................................33 
 Data Analysis .........................................................................................................35 
  
iv 
 
 
 
Chapter          Page 
 
 
IV. FINDINGS .............................................................................................................37 
 
 Description of the Study Population ......................................................................37 
 Bone Densitometry ................................................................................................42 
 Biochemical Markers of Bone Metabolism ...........................................................46 
 Cytokines and Complete Blood Count ..................................................................48 
 Vitamin D...............................................................................................................52 
 
 
V.  DISCUSSION ........................................................................................................54 
 
 
VI. CONCLUSION......................................................................................................60 
 
 Summary ................................................................................................................60 
 Purpose ...................................................................................................................61 
 Hypotheses .............................................................................................................61 
  Hypothesis 1.....................................................................................................61 
  Hypothesis 2.....................................................................................................62 
  Hypothesis 3.....................................................................................................62 
 Recommendations ..................................................................................................62 
  
REFERENCES ............................................................................................................64 
 
 
APPENDICES .............................................................................................................93 
 
A. DXA Measurement of the Hip Regions at Baseline and Final Visit ..................94 
B. DXA Measurement of the Spine and Forearm at Baseline and Final Visit ........95 
C. Consent Form ......................................................................................................96 
D. Medical History Form                                                                                        101 
E. Tribal Representation Form                                                                               105 
v 
 
LIST OF TABLES 
 
 
Table           Page 
 
   1. Baseline Descriptive Characteristics of Groups According to Diabetes Mellitus (DM) 
Status. ...........................................................................................................................38 
   2. Self-Reported Osteoporosis Diagnosis, Fracture History and Medication Use of 
Groups by DM Status at Baseline. ...............................................................................40 
   3. Frequency of Osteopenia and Osteoporosis of the Hip, Spine and Forearm by 
Diabetes Status .............................................................................................................41 
   4. Percent Change in Bone Mineral Area, Content, Density and T-scores from Baseline 
to Final Visit According to Diabetes Status. ................................................................45 
   5. Serum Markers of Inflammation, Lymphocyte and Monocyte Counts at Baseline and 
Final Visit According to Diabetes Status. ....................................................................51 
 
 
 
vi 
 
LIST OF FIGURES 
 
Figure           Page 
 
   1. BMD of the total hip, intertrochanter, trochanter and femoral neck regions of the hip.
......................................................................................................................................42 
   2. BMD of the total lumbar spine and distal forearm. ..............................................43 
   3. BMD values of total hip, intertrochanter and trochanter at final visit. .................44 
   4. Percent change in BMD of total hip and intertrochanter region of the hip over one 
year ...............................................................................................................................46 
   5. Serum C-telopeptide of type I collagen (CTX) concentrations at baseline and final 
visits .............................................................................................................................47 
   6. Serum bone alkaline phosphatase (BAP) concentrations at baseline and final visit.
......................................................................................................................................48 
   7. Serum TNF-α concentrations at baseline and final visit for non diabetic (Non DM), 
all diabetic (All DM),diabetic less than 10 years duration from diagnosis (DM<10) and 
diabetic 10 years or greater post-diagnosis (DM≥10) groups. .....................................49 
   8. Serum IL-6 concentrations at baseline and final visit for non-diabetic (Non DM), all 
diabetic (All DM),diabetic less than 10 years duration from diagnosis (DM<10) and 
diabetic 10 years or greater post-diagnosis (DM≥10) groups. .....................................50 
   9. Correlation of CTX to TNF-α in the non diabetic (Non DM) group and the all 
diabetic (All DM) group at baseline visit. ...................................................................52 
 10. Serum 25-hydroxyvitamin D concentrations of non diabetic (Non DM), all diabetic 
(All DM),diabetic less than 10 years from diagnosis (DM<10) and diabetic 10 years or 
greater post-diagnosis (DM≥10) groups at baseline and final visits ............................53 
 
 
 
 
 
 
 
 
1 
 
CHAPTER I 
 
 
INTRODUCTION 
 
Background 
Native Americans are often recognized for honoring traditions and preserving the culture of 
individual tribes (1-3). However, in recent generations there has been an extrinsic attribute 
invading Native cultures in the form of pervasive health disparities and chronic disease. 
Numerous obstacles including mistrust from previous scientific exploitation, linguistic and 
cultural dissimilarities, lack of culturally grounded theory and methods, and limited or selective 
access to community members, have impeded research in this population (4). One of these 
chronic diseases is type 2 diabetes which is associated with a state of low-grade, chronic systemic 
inflammation (5). Evidence demonstrates a relationship between type 2 diabetes and multiple 
microvascular (e.g. retinopathy and neuropathy) and macrovascular complications (e.g. coronary 
heart disease) and, more recently, an increased risk of bone fracture has been suggested (6-8). 
Because the prevalence of type 2 diabetes is high among Native Americans (i.e. ~ 2 times the 
national average) (9) and the availability of evidence regarding bone health is limited in this 
population, there is an emergent need to investigate the relationship between bone health and type 
2 diabetes in Native Americans.  
Osteoporosis is a skeletal condition often characterized by normally mineralized bone tissue but 
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decreased bone mass (10). The structural integrity of trabecular, or spongy bone may be 
compromised, causing it to lose elasticity and cortical bone, may become more porous and thin. 
While thinner bone alone is not necessarily more prone to fracture, bone that is both thinner and has 
compromised biomechanical properties is more prone to fracture (11). Osteoporosis is reportedly 
responsible for more than 1.5 million fractures in the U.S. annually and carries an estimated health 
care cost of $16.9 billion making this a major medical problem (12). Lifestyle factors including 
smoking, low levels of weight-bearing physical activity and compromised nutritional status can 
further contribute to fracture risk. Estimates from the 2004 Surgeon General’s Report (13) indicate 
half of all women >50 years of age will experience an osteoporosis-related fracture during their 
lifetime.   
Osteoporosis is diagnosed based on the occurrence of osteoporotic-related fracture or by assessment 
of bone mineral density (BMD), which accounts for approximately 70% bone strength, and fracture 
incidence (14). According to the World Health Organization (WHO) criteria, individuals with a BMD 
2.5 standard deviations or more below the mean value for young, healthy, Caucasian women (i.e. T-
score of < -2.5 SD) are considered osteoporotic (15;16). The most widely validated method for 
assessing BMD is an areal assessment dual energy X-ray absorptiometry (DXA) (17). 
A misconception exists that osteoporosis is always a result of bone loss, when in fact bone loss is a 
common occurrence as both women and men age. Women however, typically have a lower peak bone 
mass than men (18) and experience rapid bone loss during the first 5-10 years of the postmenopausal 
period (19). The combination of bone loss relative to peak bone mass and the rate of postmenopausal 
bone loss results in an increased risk for fracture in women earlier than men. The hormonal changes 
associated with menopause (e.g., decrease in estrogen and increase in follicle stimulating hormone) 
can lead to a disruption of normal bone metabolism which is described as a dynamic, lifelong process 
involving the coordinated activities of bone-resorping osteoclasts and bone-forming osteoblasts (20).  
The bone remodeling cycle is regulated not only by hormones, but also cytokines (e.g., interleukin or 
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(IL)-6 and tumor necrosis factor (or TNF-α) and growth factors (21;22). These regulatory proteins 
can be influenced by a number of factors, including nutritional status (e.g. compromised vitamin D 
status), physical activity, age and illness, which subsequently alter bone turnover (23). When 
considering that type 2 diabetes also has a profound impact on many of these same nutritional, 
cytokine and hormonal factors the consequences on bone remodeling have the potential to be 
significant (24). This relationship is in part the impetus behind an increasing interest in the effects of 
type 2 diabetes on bone health. 
Several studies have provided clinical evidence of an increased fracture risk in type 2 diabetics 
compared to the general public (7;8;25-31). Results of the Iowa Women’s Health Study reported a 
1.70-fold increased risk of hip fracture in post-menopausal women with type 2 diabetes compared to 
their non-diabetic counterparts (25). Duration of diabetes appeared causative to even higher risk for 
hip fracture, considering those women 13 to 40 years post-diagnosis had a 2.30-fold higher risk for 
hip fracture relative to women without diabetes. The increased risk for hip fracture was observed in 
both obese participants, known to benefit from greater skeletal loading, as well as non-obese women 
with type 2 diabetes (25). A higher fracture risk among type 2 diabetics was also found in the Health, 
Aging and Body Composition Study (Health ABC) (26). Results of this biracial cohort of elderly men 
and women demonstrated that type 2 diabetes was associated with a 64% increase in incident clinical 
fractures compared to non-diabetics. Participants in this study with type 2 diabetes had similar BMD 
and significantly higher body weight, BMI, lean and fat mass, visceral fat and fasting insulin 
compared to their non-diabetic counterparts. These studies provide data in support of an increased 
risk of fracture in the type 2 diabetic population.  
Native Americans are a high-risk population for type 2 diabetes. Data from the 2005 Indian Health 
Services (IHS) user population database indicate that 16.5% of the total adult population served by 
IHS had diagnosed diabetes compared to 7.8% of the total U.S. adult population (9). In addition to 
diabetes, factors such as smoking (32) and low serum vitamin D (33) contribute as risk factors for 
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bone fracture in this population. Unfortunately, there is a paucity of data regarding Native American 
women and bone health substantiating increased risk. In the National Osteoporosis Risk Assessment 
(NORA), Native Americans represented 0.9% of the total population. Results from this study 
indicated that body weight could explain differences in BMD found among White, Native American, 
Hispanic and Asian women (34). Among limitations identified in this study were selection bias due to 
eligibility criteria, reliance on self-reported information and insufficient numbers (34). Other data 
from the Women’s Health Initiative (WHI) suggest that overall, American Indian/Alaska Natives 
(AI/AN) and non-Hispanic white women had similar BMDs, after adjusting for age, education, and 
years of hormone therapy (35). Both the NORA and WHI reports represent large scale research 
studies that acknowledge as limitations the low or insufficient number of Native American 
participants and eligibility criteria excluding diabetics from participation.  
Problem Statement:  
Despite these efforts to examine the risk of osteoporosis in Native American’s, the issue of fracture 
risk and the potential influence of type 2 diabetes on bone health in this population remains to be 
addressed.  
Purpose: 
The purpose of this study is to examine the effects of type 2 diabetes and diabetes duration on bone 
health compared to non-diabetics in Native American women over 50 years of age. To accomplish 
this purpose the following hypotheses have been developed. 
Hypotheses and Specific Aims: 
Hypothesis 1:  Change in BMD from baseline to final visit, one year later, will be greater in those 
women with type 2 diabetes and especially those women who have been diabetic for ten or more 
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years compared to their non-diabetic counterparts. To test this hypothesis the following specific aims 
have been developed: 
Specific Aim 1a: To examine differences in change in BMD between diabetics and non diabetics by 
performing DXA scans of the three principal sites of osteoporotic fracture, spine, total hip and 
forearm, at baseline and at one year follow-up.   
Specific Aim 1b: To examine differences in change in BMD between diabetics stratified by duration 
of diabetes diagnosis (<10 or ≥10 years) and non diabetics over a one year period. 
Hypothesis 2:  Type 2 diabetics will demonstrate alterations in bone metabolism consistent with 
increased bone resorption and decreased bone formation rates from baseline to final visit, compared 
to non-diabetics. These alterations in bone metabolism will be more pronounced in longer duration 
type 2 diabetics (i.e., > 10 yrs). The following aims have been developed to test this hypothesis: 
Specific Aim 2a: To evaluate differences over time in serum markers of bone resorption, as indicated 
by C-telopeptide or CTX in type 2 diabetics compared to non diabetics.  
Specific Aim 2b: To evaluate differences over time in serum markers of bone formation as indicated 
by bone-specific alkaline phosphatase (BAP) in type 2 diabetics compared to non diabetics. 
Specific Aim 2c: To evaluate differences over time in serum CTX and BAP in diabetics stratified by 
duration of diabetes diagnosis (<10 or ≥10 years) compared to non diabetics. 
Hypothesis 3:  The mechanisms by which type 2 diabetics will experience accelerated bone loss will 
be mediated by an increased inflammatory state and compromised vitamin D status. The increased 
inflammatory state and compromise in vitamin D status will be exacerbated in longer duration 
diabetics. The following aims have been developed to test this hypothesis: 
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Specific Aim 3a: To examine differences in change in serum IL-6 and TNF-α in type 2 diabetics vs. 
non-diabetics between baseline and final visits. 
Specific Aim 3b: To examine differences in change in monocyte and lymphocyte percentage and 
absolute counts based on complete blood counts (CBC) in type 2 diabetics vs. non-diabetics between 
baseline and final visits. 
 Specific Aim 3c: To evaluate differences in change in vitamin D status via 25-hydroxyvitamin D3, in 
type 2 diabetics vs. non-diabetics over time. 
Specific Aim 3d: To examine differences in change in inflammatory indices and vitamin D status 
when type 2 diabetics are stratified by duration of diabetes diagnosis (<10 or ≥10 years). 
 Limitations: 
Some of the limitations of this study include external validity due to the small (N=123), unique 
sample (stratified by diabetes diagnosis) available for the study. Therefore, results may not be 
generalizable beyond the specific population from which the sample was drawn. Additionally, the 
accuracy of results such as medical history, medications and supplements, and calcium intake was 
dependent on the self-report of the participants. Data provided that were crucial to the accuracy of this 
study included diabetes diagnosis and blood quantum information.  
Delimitations: 
This study is delimited to Native American women, who were 50 years of age and older and eligible 
to receive services at an Indian Health Clinic. The study was delimited to examination of changes in 
BMD, measures of bone formation and resorption, vitamin D status and markers of inflammation 
over the duration of one year to determine the impact of type 2 diabetes on bone health. Due to the 
large number of potential participants in the study population, recruitment efforts were concentrated 
within the state of Oklahoma.
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Bone Tissue 
Bone is a living, dynamic tissue that is constantly renewed, resulting in complete turnover of the 
adult skeleton every 10 years (36). Bone tissue is generally classified into two types, cortical and 
trabecular bone, which are identical in their chemical composition. Cortical bone is a dense, 
compact structure, highly resistant to bending and torsion, and except for the periosteum, has a 
slow turnover rate. It constitutes the diaphysis of long bones and the outer part of all skeletal 
structures. It functions primarily to provide mechanical strength and protection to vital organs. 
Trabecular bone is less dense, more elastic and has a higher turnover rate than cortical bone. 
Anatomical sites rich in trabecular bone include the epiphyses and metaphyses of the long bones 
and it is also the major component of the ribs, the shoulder blades and the flat bones of the skull. 
In addition to providing strength and support for the body, bone serves as a site for development 
and storage of blood cells. Bone accumulates micro-damage from loading, but is unique in its 
ability to self-repair (37-39). The complexities and processes involved in the anabolic and 
catabolic aspects of bone metabolism (i.e., formation by osteoblasts and resorption by 
osteoclasts), and the influence of nutritional and environmental factors all contribute to the 
susceptibility for diseases and disorders to potentially affect bone health.   
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Osteoporosis Defined 
Osteoporosis is a skeletal disorder characterized by compromised bone strength with a 
consequent increased risk of fracture (40;41). Prediction of fracture risk is a key element in 
fracture prevention. As a result, the definition of osteoporosis has evolved over the years in an 
effort to improve predictive ability.  
In 1941 Fuller Albright, a research endocrinologist, observed thinning bones in women following 
menopause (42). He was the first to propose that estrogen deficiency played a primary role in 
postmenopausal osteoporosis. Albright’s definition of osteoporosis was described as “too little 
calcified bone” due to the osteoblast’s inability to lay sufficient osseous matrix (42).   
It was not until 1994 that osteoporosis was formally defined by the World Health Organization 
(WHO) in terms of BMD and fracture history (15). This was a result of the efforts of an 
international panel of scientific experts to assess fracture risk and its application to screening for 
postmenopausal osteoporosis. The panel considered several approaches to defining osteoporosis 
based on bone mineral measurement, but each failed to overcome the problem of overlap in BMD 
between those who have and those who have not suffered fragility fractures. The determination 
was made that bone mineral assessment may provide an index of risk, much as 
hypercholesterolemia is a risk for coronary heart disease, but that index was not reflective of all 
elements of risk. Subsequently the panel established four general diagnostic categories for women 
based on bone mineral content and proximity to the young adult reference mean. These categories 
include normal, osteopenia, osteoporosis and severe osteoporosis (43). The panel further 
emphasized the importance of distinguishing between the diagnostic use of BMD measurements 
by providing information concerning the presence or absence of osteoporosis with the cut-off 
values chosen, and the prognostic use whereby bone density values are considered a risk factor 
(43). 
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Risk Factors for Osteoporosis 
The 1994 report of the international WHO conference identified the role of osteoporosis in 
predicting fracture risk (43). Because no obvious warning signs precede the clinical manifestation 
of osteoporosis, identification of risk factors for reducing fracture risk was considered of great 
importance. 
Thus osteoporosis, once viewed primarily as a natural occurrence of aging, was now recognized 
as a condition that can stem from suboptimal bone mineralization during childhood and 
adolescence (44-47), or from bone loss later in life. Bone health is influenced by factors both 
modifiable and non-modifiable.   
Modifiable Risk Factors 
Among the factors affecting bone health that are modified or controlled is diet. A diet low in 
calcium and vitamin D has been shown to increase risk of osteoporosis and fractures (48-51). A 
low calcium intake can contribute to osteoporosis and fracture risk by enhancing parathyroid 
hormone (PTH) release from the parathyroid glands, resulting in excessive bone turnover in favor 
of bone resorption and eventual bone loss. Studies have demonstrated that calcium 
supplementation for elderly women are associated with a reduction in bone resorption and a 
partial suppression of serum PTH (52;53).   
Vitamin D, well known for enhancing calcium absorption in the gut, is also critical for 
maintenance of bone mass through its actions on other cellular processes such as bone 
mineralization. Vitamin D facilitates bone mineralization at the osteoblast level by enhancing 
differentiation and stimulates proximal tubular phosphate reabsorption in the kidney. The latter 
function enhances bone mineralization by contributing phosphate, one of the two principal 
crystalline salts deposited in the mineralized matrix of bone. The combination of calcium and 
phosphate with hydroxide form hydroxyapatite crystals, which constitutes the mineral phase of 
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bone tissue (54). A meta-analysis performed by Papadimitropoulos et al. (55), examined all 
randomized placebo-controlled trials of vitamin D and its analogs over the last two decades. They 
reported a significant reduction in spine fractures (i.e., 37% risk reduction) in women taking 
vitamin D compared to placebo. Other research supporting beneficial effects of dietary calcium 
and vitamin D includes Chapuy et al. (48) who dispensed 800 international units (IU) of 
cholecalciferol or vitamin D3 and 1200 mg of calcium to nursing home residents for 18 months. 
A 35% reduction in the occurrence of hip fractures was reported with this supplement regimen 
(48). Similarly, Dawson-Hughes et al. (49) reported that elderly men and women treated with 700 
IU of cholecalciferol plus 500 mg of calcium citrate a nearly 50% reduction in nonvertebral 
fractures (49).Thus supporting the effectiveness of adequate consumption of calcium and vitamin 
D.  
Physical activity is also a modifiable risk factor that affects bone remodeling (56-60). The 
microgravity environment of space flight is an extreme example of deficient weight-bearing 
activity, which results in a significant decrease in bone formation (61;62). Skeletal unloading has 
been shown to decrease osteoblast activity and number (63-70), which according to Garetto et al. 
(71) is likely due to a decreased proliferation of osteoprogenitor cells. The weightless 
environment of space has also been shown by Smith et al. (72) to affect bone resorption. This was 
demonstrated based on astronauts’ post flight elevation (50-125%) in urinary collagen cross-links 
(N-telopeptide [NTX], deoxypyridinoline [DPD], and pyridinoline [PYD]). A somewhat less 
extreme example of the effect of inactivity is found in bed rest where the rate of loss has been 
observed to be one to two percent per month (73). In contrast, Howe et al. (74) demonstrated in 
an extensive review that weight-bearing exercise had a significantly greater effect on BMD in 
post-menopausal women compared with controls who did not exercise. 
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Non-Modifiable Risk Factors 
Apart from modifiable risk factors are those that cannot be controlled. These risk factors include 
among others, gender, age and race. There is evidence to support the relationship between 
menopausal status and BMD thus contributing to the greater risk of development of osteoporosis 
in women than men. Results of numerous studies have demonstrated a negative association 
between either menopausal status or years post-menopause and BMD (75-80). Two separate 
studies of the same population reported that post-menopausal status was associated with a 
decrease in both femoral neck and spinal BMD (75;76). Mizuno et al. (80) also reported that after 
menopause, BMD of the lumbar spine (L2-4) decreased more rapidly than other anatomical sites. 
The correlation coefficient between lumbar spine BMD and lumbar spine/total body BMD ratio 
was 0.746, indicating that a decreasing ratio of lumbar spine (L2-4) BMD was more prominent 
than that of total body BMD. Perimenopause, defined as the two to eight year period preceding 
menopause and one year following the last period, is marked by an increase in bone loss which is 
a result of increased bone resorption (81). Greater bone loss is observed in trabecular-rich regions 
compared to sites higher in cortical bone due to the larger surface area over which osteoclasts can 
attach and degrade bone. The result of perimenopausal bone loss is demonstrated in the fractures 
occurring in early menopause in the trabecular-rich skeletal regions of the distal forearm and 
vertebrae (82).  
Although differences in BMD between men and women may explain in part the gender-related 
differences in fracture rates, it is also possible that differences in both BMD and fracture rates 
may be attributed to differences in bone size and geometry (83-86). The geometry and structure 
of bone have been increasingly recognized as important risk factors for fracture including the role 
of puberty on bone growth. It has been shown that the length and width of bone increase 
progressively throughout the pre-pubertal period, in both sexes (87). Because boys enter puberty 
approximately two years later than girls, boys can acquire greater long bone length before puberty 
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(88). Gender-related differences in bone width are more apparent after puberty as demonstrated 
by periosteal growth. This enlargement in bone diameter is the result of bone formation beneath 
the periosteal envelope causing a widening of the diaphysis of the bone and stimulating 
longitudinal bone growth (88). This process is accelerated by puberty in males, but inhibited 
during puberty in females due to the increases in circulating estrogen (87). These differences in 
bone development contribute to the greater attainment of peak bone mass in males which is 
considered a major determinant of bone mass and fracture risk in later life (89).  
Age represents another non-modifiable risk factor for osteoporosis. A progressive reduction in 
BMD with aging has been documented at nearly every skeletal site (90), however fracture risk 
has shown an increase with age independent of BMD (91). Other factors influenced by age 
include degree of mineralization, microfracture, number and frequency, skeletal geometry and 
periosteal response to trabecular bone loss. Additionally, greater periosteal apposition has been 
demonstrated more in aging men than women. This contributes to a greater net bone loss in 
women compared with men (92) which may in turn propagate the higher fracture rate seen in 
women.  
Race is another risk factor for osteoporosis. Although each group is comprised of unique 
characteristics that set them apart from the others, one of the challenges of examining racial 
differences is the absence of an obvious or uniform method of classification of individuals into 
such groups. Racial differences in bone health have been associated with several key features.  
Differences in body size (93;94), bone size (95), rate of skeletal loss (96-99), and hip geometry 
(100-103) have all been reported to partially explain observed differences in fracture risk among 
races. These differences have multifactorial explanations including differences in bone 
metabolism (104) and pubertal onset (105). Longitudinal data with baseline BMD and fracture 
outcomes for nonwhites are limited and it is also unknown whether T-scores obtained by BMD 
measurement in nonwhite women have the same value in terms of fracture prediction (106). It is 
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important therefore, for future osteoporosis research to continue to examine variables that 
contribute to observed racial differences.  
Gastrointestinal conditions are also included among the non-modifiable risk factors for 
osteoporosis. Underlying in many conditions is malabsorption of vitamins and minerals, 
particularly vitamin D (107) and calcium (108). There is consistent evidence of a reduction in 
BMD in patients with both Crohn’s disease and ulcerative colitis resulting from a decrease in 
bone formation and an increase in bone resorption (109-111). Calcium malabsorption in 
gastrointestinal conditions has been associated with steatorrhea, alteration in the calcium-
transport mechanisms, and lack of vitamin D (112-116). Contributing to vitamin D malabsorption 
are chronic pancreatic insufficiency, intrinsic small bowel disease, disorders of the biliary tract, 
and surgical bypass procedures of the jejunum and ileum. Leichtmann et al. (117) reported the 
small intestine involvement in Crohn’s disease leads to an increase in vitamin D malabsorption 
and subsequently increased bone loss. In fact vitamin D deficiency in Crohn’s has been shown to 
be a predictive factor for osteoporosis and osteopenia (117;118).  
In addition to malabsorption, gastrointestinal conditions including inflammatory bowel disease 
(IBD) and celiac disease increase fracture risk through the chronic release of pro-inflammatory 
cytokines by immunologically competent cells. Osteotropic cytokines such as TNF-α and IL-6 are 
involved in both normal and abnormal bone remodeling, and increased cytokine production in 
chronic inflammatory diseases is associated with increased bone loss (119;120). 
Endocrine disorders contribute to osteoporosis risk via the role of hormonal regulation of the 
bone remodeling cycle. For example, the chronic secretion of PTH (i.e., hyperparathyroidism) or 
the continuous infusion of PTH can lead to decalcification of bone and loss of bone mass. The 
regulation of calcium homeostasis is a process maintained in large part by PTH via secretion in 
response to very small decrements in blood ionized calcium. The action of PTH on calcium 
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homeostasis is accomplished by: 1) promotion of bone resorption (i.e., release of calcium from 
the skeletal reservoir); 2) induction of renal calcium conservation and phosphate excretion; and 3) 
indirect enhancement of intestinal calcium absorption by increasing the renal production of the 
active vitamin D metabolite, 1,25(OH)2 vitamin D. PTH has been shown in vivo to increase the 
numbers of osteoclasts as well as the resorptive activity of preformed osteoclasts (121).  
One hormone that contributes as a risk factor for osteoporosis post-menopause is estrogen. A 
major physiological effect of this hormone is inhibition of bone resorption (122), as such it plays 
a regulatory role in osteoclast apoptosis (123). In estrogen deficiency, an increased number of 
osteoclasts and their extended longevity lead to increased bone resorption. In response to the 
increased bone resorption, there is increased bone formation and a high-turnover state develops 
favoring resorption and leading to rapid bone loss and perforation of the trabecular plates (124). 
In addition, estrogen elicits a protective effect on bone through its ability to decrease pro-
osteoclastogenic cytokines. For example decreases in estrogen levels at menopause have been 
associated with an increase in serum interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 7 (IL-7) 
and TNF-α which are known to promote osteoclast differentiation and activity (125-127).  
Another hormone influencing bone remodeling is insulin. Current evidence suggests insulin 
impacts bone development and physiology by regulating osteoblast function in the following 
manner. Osteoblasts express a functional insulin receptor (IR) and when primary osteoblasts or 
osteoblast-like cell lines are exposed to physiological levels of insulin, increases are observed in 
bone anabolic activity such as collagen synthesis (128;129) and alkaline phosphatase production 
(130). In addition, it has been demonstrated that patients with type 1 diabetes develop early onset 
osteopenia or osteoporosis (131;132), experience increased risk of fragility fracture (25;133) and 
exhibit poor bone healing and regeneration after injury (134). A recent discovery by Fulzele et al. 
(135) demonstrated that insulin suppresses the runt-related transcription factor 2 (Runx2) 
inhibitor Twist-related protein 2 (Twist2). Runx2 is a key transcription factor regulating gene 
15 
 
expression for several key bone proteins, including osteocalcin, osteopontin and osteoprotegeron 
(136-139). Twist2 inhibition in turn promotes osteoblast differentiation necessary for normal 
bone formation. In addition, previous clinical studies clearly demonstrate that an oral glucose 
load which increases insulin secretion suppresses markers of bone resorption by 50% (140). 
These findings provide a basis for the discrepancy in BMD between the type 1and type 2 diabetic 
populations which is related to their opposing insulin-secretory states (i.e. hypoinsulinemia vs. 
hyperinsulinemia). 
Obesity and Type 2 Diabetes 
Obesity is a major public health problem in our society. According to data from the 1999-2000 
National Health and Nutrition Examination Survey (NHANES) (141) almost 65% of the adult 
population in the United States is overweight or obese (body mass index [BMI] 25-29.9; > 
30kg/m2). Health concerns related to increased prevalence of obesity stem from the 
accompanying increased risk of chronic disease, particularly type 2 diabetes (142;143).   
In general, obesity is defined as excess adipose tissue. This tissue is found in the human body in 
two types, brown adipose tissue and white adipose tissue. Adipocytes found in brown adipose 
tissue are specialized primarily for non-shivering thermogenesis (144). Brown fat depots are 
present in human infants and recent evidence suggests that dispersed brown adipocytes might 
persist in adults (145). In contrast, white adipose tissue is the predominant type found in adults 
and is located just beneath the skin as subcutaneous fat, around the organs as visceral fat and 
within the bone marrow. Adipocytes found in white adipose tissue store dietary energy in the 
form of triglycerides, predominantly in single large, lipid droplets. The droplets’ unique structure 
allow triglycerides to be rapidly hydrolyzed by lipases in a process known as lipolysis, and the 
resulting fatty acids are transported to other tissues to be oxidized in mitochondria for energy.    
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Adipose tissue is now considered the largest endocrine organ in the body (146).The endocrine 
action of adipose tissue is via adipocyte secretion of a number of protein factors, collectively 
referred to as adipokines which include growth factors (e.g., transforming growth factor (TGF)-ß) 
and hormones (e.g., leptin and adiponectin). Leptin is well known for its regulatory role in energy 
metabolism by stimulating energy expenditure, inhibiting food intake and restoring euglycemia. 
In obesity however, leptin resistance often limits the effectiveness of this process (147-149). In 
contrast to leptin, adiponectin has been associated with an anti-inflammatory action (150) and 
when increased in plasma, has been independently associated with reduced risk of type 2 diabetes 
in healthy individuals (151).  
Two other cytokines secreted by adipose tissue are interleukin (IL)-6 and TNF-α. Serum levels of 
these pro-inflammatory cytokines have been reported to be elevated in the obese (152;153), 
contributing to the concept that obesity and diabetes are characterized by a state of chronic low-
grade inflammation (153-155).  
A number of studies have demonstrated that TNF-α can impair insulin signaling in hepatocytes 
and adipose tissue (156-158). The underlying mechanism involves the inhibition of insulin 
receptor substrate (IRS) signaling capability. IRS proteins act as mediators of insulin signaling 
playing a central role in maintaining basic cellular functions such as growth and metabolism by 
acting as docking proteins between the insulin receptor and a complex network of intracellular 
signaling molecules. The inhibition of this signaling is thought to be achieved through the TNF-α 
activation of serine kinases such as the c-Jun-N-terminal kinase (JNK) (159;160). Although 
understanding of the signaling network of JNKs continues to evolve (161), JNK1 knockout mice 
have been shown to exhibit decreased adiposity and significantly increased insulin sensitivity 
(162). TNF-α also affects insulin action by reducing fatty acid oxidation in hepatocytes (163) and 
skeletal muscle (164). These affects are mediated by suppression of adenosine monophosphate-
activated protein kinase (AMPK) via the up-regulation of protein phosphatase 2C (PP2C). In 
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skeletal muscles, AMPK stimulates glucose transport and fatty acid oxidation. In the liver, it 
decreases cholesterol and triglyceride synthesis, glucose output and augments fatty acid 
oxidation. The reduced rates of fatty acid oxidation subsequently increase accumulation of 
bioactive lipids, such as diacyglycerols (164), which in turn activates protein kinase C and 
inhibits IRS function (165).  
The association between elevated serum IL-6 and insulin resistance is supported by 
epidemiological and genetic studies. IL-6 has been demonstrated to inhibit the insulin signaling 
pathway in adipocytes by up-regulating suppressor of cytokine signaling (SOCS) 3 expression, 
which in turn impairs insulin-induced insulin receptor and IRS-1 phosphorylation (166-168), 
resulting in increased insulin resistance. Clinically, plasma IL-6 has been shown to positively 
correlate with both obesity and insulin resistance (169;170). In fact, Pradhan et al. (171) found 
elevated plasma IL-6 to be a predictive marker in the development of type 2 diabetes. The 
association between IL-6 and type 2 diabetes remained positive after adjusting for BMI, family 
history of diabetes, smoking, physical activity, alcohol use, and hormone replacement therapy. 
This finding supports the possibility of a causal relationship between IL-6 and the development of 
diabetes.  
Although it may appear logical that adipose tissue expression of adipocytokines plays a role in 
the development of type 2 diabetes based on total adiposity, other factors such as the size of 
adipocytes and fat distribution may also contribute to insulin resistance. Recently, the influence 
of adipocyte size has been given much attention from the scientific community due to the 
discovery that larger adipocytes are more likely to become insulin resistant (172). For instance, in 
Pima Indians, who have a very high prevalence rate of type 2 diabetes, larger adipocytes were 
shown to have a greater propensity for insulin resistance, which led to reduced triglyceride and 
glucose clearance (173). These data indicated that large adipocytes and increased circulating fatty 
acids were independent predictors of diabetes risk in this population.    
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It has also been suggested that insulin resistance can be attributed to a defect in subcutaneous 
adipose tissue’s ability to expand appropriately as indicated by telomere length (174-176), 
independent of body weight (177). In fact, hyperplastic obesity is typically more metabolically 
benign in terms of insulin sensitivity than fat hypertrophy (178). A study by McLaughlin et al. 
(179) aimed at identifying insulin-resistant individuals, found that 17% of the overweight and 
obese subjects were relatively insulin sensitive. Moreover, Karelis et al. (180) reported that 
approximately 20% of the general population were obese but metabolically healthy, which 
reinforces the influence of body composition in the development of diabetes. 
Distribution of adipose tissue is also an important influence on insulin sensitivity. One area that 
has been studied for its influence on insulin resistance is adipose tissue of the visceral depots 
(181). Increased adiposity of the intra-abdominal fat area (IAFA) was found by Boyko et al. (182) 
to be predictive of diabetes incidence. This observation was independent of other measures of 
total and regional adiposity, family history of diabetes, gender, correlates of insulin resistance 
(fasting C-peptide) and glycemia (fasting glucose). This is consistent with other studies that have 
demonstrated visceral adipose tissue was significantly correlated with both insulin resistance and 
type 2 diabetes (183-186). The primary regional difference between the two compartments 
appears to be in the rate of lipolysis (187). The rate of release of free fatty acids (FFAs) from 
stored triglycerides is higher in visceral adipocytes than subcutaneous where anti-lipolytic 
hormones, such as insulin, have a more pronounced effect (188). Because visceral fat drains into 
the portal vein, rapid visceral lipid metabolism results in the delivery of excessive amounts of 
FFA concentrations to the liver. This in turn leads to stimulation of gluconeogenesis, increased 
triglyceride synthesis and inhibition of insulin clearance. The result of these metabolic alterations 
may ultimately lead to the development of hyperglycemia and hyperinsulinemia (188).  
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Obesity and Bone Health 
Obesity and its association with chronic diseases such as type 2 diabetes, hypertension, coronary 
heart disease and some cancers pose a serious health threat to our society (142;143). The 
association between obesity and skeletal health may not be as obvious. This is due in part to 
higher BMI values having been traditionally considered a protective feature against osteoporotic 
related fracture risk (189-192). In fact body weight and BMI are positively correlated to BMD 
(193-196) in adults (193;197-199). The increasing prevalence of obesity in our society however, 
does not support the beneficial effects of increased BMI on fracture prevention.   
Epidemiologic studies have demonstrated some common genetic determinants between obesity 
and osteoporosis. Both adipocytes and osteoblasts originate from common progenitor, pluripotent 
mesenchymal stromal cells (MSC) (200-202). The fate of these cells’ differentiation is largely 
determined by the expression of transcription factors, Runx2 and peroxisome proliferator-
activated receptor gamma (PPARγ). These transcription factors act as molecular switches to 
promote the direction of differentiation of precursor cells into osteoblast or adipocyte lineages, 
respectively (203-205). Animal models have demonstrated that decreased PPARγ activity leads to 
increased number of osteoblasts and bone mass (206;207). Inversely, increased PPARγ activity, 
related to antidiabetic treatment with the thiazolidinedione (TZD) drug rosiglitazone, has resulted 
in significant decreases in BMD, bone volume and changes in bone microarchitecture (208-211). 
This bone loss has been associated with a decreased number of osteoblasts and an increased 
number of adipocytes within the bone marrow (198;201). PPARγ expression has been found at its 
highest levels in white adipose tissue (212-215).  
Another feature that highlights the relationship between obesity and the bone remodeling cycle is 
hormonal. The hormone leptin is secreted by adipocytes and well known for its role in the 
regulation of appetite and energy expenditure (216). More recently leptin has been examined for 
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its role in bone remodeling. The effects of leptin via a central hypothalamic pathway were first 
reported by Ducy et al. (216), wherein he described the action of leptin on neurons in the 
hypothalamus which has since been proposed to regulate bone mass as well (217). The 
mechanism by which leptin influences bone metabolism is at least in part through activation of 
hypothalamic nerves. This in turn stimulates sympathetic nerves extending into the bone and 
promoting the release of the neurotransmitter noradrenaline (217). Noradrenaline stimulates ß2-
adrenergic receptors (ADRB2). ADRB2 upregulation decreases osteoblast activity and bone 
formation, and increases bone resorption via receptor activator for nuclear factor κB (NF-κB) 
ligand (RANKL) production, which ultimately leads to trabecular bone loss (216-222). These 
complex interactions between fat, brain and bone are further explained by the effects of pro-
inflammatory mediators (e.g., TNF-α and IL-6) on bone metabolism (223).  
Obesity, IL-6 and Bone 
Adipose tissue is responsible for secretion of one third of all circulating IL-6 which explains why 
overweight and obese adults and children generally have elevated serum IL-6 (153;224). 
Cytokines that promote bone resorption such as TNF-α and IL-1 also reportedly stimulate the 
synthesis of IL-6 in osteoblasts (225-227). In the context of chronic inflammation, the role of IL-
6 is central to the pathogenesis of bone loss, exerting its effects as a potent stimulator of 
osteoclast-induced bone resorption (228). These effects are demonstrated in the osteopenia 
observed in transgenic mice overexpressing IL-6, characterized by severe alterations in cortical 
and trabecular bone microarchitecture. Also reported is the uncoupling of bone formation and 
resorption, evidenced by decreased osteoblast and increased osteoclast number and activity (228). 
The role of IL-6 in osteoporosis has been further highlighted in a study of the expression of key 
regulatory molecules of bone remodeling in fragility fracture patients who underwent total hip 
arthroplasty as a result of a femoral neck fracture (229). The fracture groups’ expression of 
RANK and IL-6 were significantly elevated compared with an age-matched control group. IL-6 
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mRNA levels associated strongly with bone mRNA levels in the fracture group, but not in the 
control group (229). These findings suggest an association between IL-6 and the RANKL/RANK 
pathway and are consistent with studies in murine osteoblastic cell lines, where IL-6 has been 
shown to induce RANKL mRNA expression (230). It is thought that IL-6 utilizes the 
RANK/RANKL/OPG interaction to exert an indirect effect on osteoclasts by promoting 
activation and subsequent bone resorption. This effect has been proposed to occur via an 
interaction between IL-6 and osteoblasts, which may lead to increased osteoblastic RANKL 
production (231).    
The effects of estrogen on IL-6 are seen in postmenopausal women as an increased secretion rate 
of IL-6 compared with baseline levels in cells from premenopausal women. Notably, the increase 
is found in the early post-menopause phase, but not in late years (232-234). Jilka et al.(125) have 
proposed that estrogen’s affect on IL-6 is through inhibition of TNF-α, and IL-1 stimulated IL-6 
gene transcription by binding the estrogen receptor ligand complex to NF-kB, therefore 
preventing binding to the IL-6 promoter (235-240). Conversely, in an estrogen deficient state, the 
inhibitory effects of estrogens are removed, resulting in enhanced osteoclast development in the 
marrow. It is this increase in osteoclastogenesis that is responsible for the increased bone 
resorption and hence the loss of bone in the post menopausal state. This effect was demonstrated 
in ovariectomized mice where the increase in osteoclast number was prevented by treatment with 
a neutralizing anti-IL-6 antibody in vivo and in ex vivo cultures (126). 
Obesity, TNF-α and Bone 
TNF-α is another proinflammatory cytokine expressed and secreted by adipose tissue (241;242).  
Though numerous factors contribute to bone loss, TNF-α plays a central role in the 
pathophysiology by increasing bone resorption while simultaneously inhibiting bone-forming 
osteoblasts (243-250). The influence of TNF-α is exerted through increased osteoclastogenesis, 
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decreased osteoblastogenesis and inducing vitamin D resistance (251). The effects of TNF-α 
serve as potent stimuli for bone loss that ultimately lead to bone microarchitectural deterioration 
and increased fracture risk that has been demonstrated in conditions such as rheumatoid arthritis 
(RA), periodontitis, orthopedic implant loosening, and other forms of chronic inflammatory 
osteolysis (252-257). 
The role of TNF-α as a stimulator of osteoclastogenesis has been confirmed by numerous 
investigators (125;258;259). Hematopoietic stem cells differentiate along the myelo-monocytic 
lineage toward an osteoclast phenotype under the influence of macrophage colony stimulating 
factor (M-CSF) and RANKL. RANKL is essential for the induction of osteoclast differentiation 
and supports survival of the mature functional osteoclast (260). TNF-α closely regulates 
RANK/RANKL-induced osteoclastogenesis, markedly increasing RANKL expression via its 
TNF type 1 receptor (TNFr1) previously shown to promote osteoclastogenesis (261;262). 
Following TNF-α and RANKL binding with their respective receptors, the transcription factor 
NF-κB enters the nucleus and activates genes coding for the mature osteoclasts including tartrate-
resistant acid phosphatase (TRAP), and the receptors for calcitonin and vitronectin (263-266). 
NF-κB functions are required for osteoclast/macrophage development as evidenced in mice 
lacking the p50 and p52 subunits of  NF-κB who fail to generate mature osteoclasts, leading to 
severe osteopetrosis or elevated BMD (266).  
TNF-α has also been shown to impair the differentiation and function of osteoblasts (252). One 
mechanism by which TNF-α impairs bone formation is through the inhibition of osteoblast 
differentiation by suppression of Runx2 (267). Runx2 is a critical transcription factor in the 
regulation of MSC toward an osteoblast lineage (136;268) and required for the expression of 
alkaline phosphatase (138;139;170;269;270), an important enzyme involved in mineral deposition 
(271;272). Mice lacking tissue non-specific alkaline phosphatase have impaired mineralization 
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(271). One of the hallmarks of bone formation is the increased expression of bone alkaline 
phosphatase (BAP) and bone specific isoforms can be measured in the serum (273).   
A second mechanism by which TNF-α affects osteoblasts is by inducing resistance to 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3) the biologically active form of vitamin D. 1,25-(OH)2D3 is 
responsible for maintaining serum calcium and phosphorus in adequate concentrations to allow 
mineralization of the bone matrix (274). 1,25-(OH)2D3 also promotes differentiation of 
osteoblasts (275) and stimulates osteoblast expression of bone-specific alkaline phosphatase 
(121;276-278). TNF-α, however, has been shown to decrease the number of vitamin D receptors 
(VDR) post-transcriptionally and also 1,25(OH)2D3-stimulated receptor transactivation in 
osteoblasts (279;280). VDR’s are required for normal 1,25(OH)2D3 function and vitamin D 
deficiencies and mutations in VDR lead to osteomalacia characterized by insufficient 
mineralization (281). Clearly, a greater understanding of the relationship between bone and fat at 
a molecular and cellular level would generate a better understanding of such processes as 
adipogenesis, lipid metabolism, and glucose homeostasis. 
Type 2 Diabetes and Bone Integrity  
Although type 2 diabetes is often accompanied by normal or even high BMD, diabetes is 
associated with long-term increased risk of fracture (7;8). Until recently, diabetes was not 
generally considered a risk factor for fracture (282), and the studies designed to evaluate this 
association often produced conflicting results (8;29;283). In the Rotterdam Study (29), evidence 
for an association between type 2 diabetes and elevated bone density was found at the proximal 
femur and lumbar spine in both men and women. A lower frequency of fractures in women with 
type 2 diabetes was also reported, however, no consideration was given to duration of diabetes. 
Heath et al.(283) reported an elevated risk of ankle fractures among women with type 2 diabetes 
24 
 
but did not find a higher risk for other fracture sites. These results were not adjusted for body size 
or BMD. 
To further examine the relationship between type 2 diabetes and risk of fractures among older 
women, Schwartz et al. (8) analyzed prospective data from the Study of Osteoporotic Fractures 
(SOF). In this cohort of 9,704 non-black women, aged 65 years and older, it was found that 
despite the elevated BMD in diabetic women, their risk of all non-spine fractures was increased 
above non-diabetic women. The increase in fracture risk has been reported to occur at 
approximately 12–14 years post diagnosis of diabetes (284). The apparent effects of prolonged 
diabetes were also seen in the Iowa Women’s Health Study where diabetics 13-40 years post 
diagnosis displayed a much higher risk for hip fracture (RR 2.30, 95% CI 1.39-3.81) than non-
diabetics (25). Similarly, increased fracture risk was also reported in the Rochester Epidemiology 
Project (285). In this study, relative risk estimates for overall fracture risk in type 2 diabetics were 
greater in the follow-up period beyond 10 years than in the first decade. For hip fractures 
specifically, the relative risks were 0.8 (95% CI, 0.6–1.1) for early follow-up, and 1.5 (95% CI, 
1.1–2.0) for late follow-up. Among women, the estimated relative risk for hip fracture in late 
follow-up was 1.5 (95% CI, 1.04–2.1), whereas it was not increased in the first decade after the 
diagnosis of diabetes (SIR, 0.7; 95% CI, 0.5–1.03). A limitation of the previous studies is the 
omission of biochemical markers of bone turnover providing evidence of the metabolic changes 
in bone that contribute to the increased fracture risk. 
The factors that contribute to greater risk of fractures reported in patients with advanced diabetes 
is uncertain, but may be due to prolonged exposure to hyperglycemia, the pro-inflammatory state, 
as well as detrimental effects of advanced glycation end products (AGE’s) on bone. Whether it is 
a single factor or a combination of several factor, a disconnect seems to occur between fracture 
risk and BMD in this patient population.  
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Factors Affecting Bone Strength  
Structural and Material Properties of Bone  
Contributing factors that determine bone strength are not only the quantity of mineralized tissue, 
but also the quality of the bone (40). Subsequently, bone quality is determined by biomechanical 
properties and describes a relationship between forces (loads) applied to bone and the resulting 
deformation. It is important to further delineate biomechanical behaviors as material or structural. 
The former is described independent of its geometry and shape and reflects the intrinsic property 
of the matrix (i.e., mineral and protein matrix), whereas the whole-bone structural behavior is 
determined by different types of loads (e.g., bending or torsion). The outcomes of these two 
measures are influenced by both material properties and geometric distribution of tissue.  
Advanced Glycation End Products and Bone Strength 
Several studies have suggested that some of the variation in bone quality may occur within the 
material properties of the collagenous protein matrix (40;286-290). More specifically, 
accumulation of AGE’s in bone collagen matrix has been linked to skeletal fragility 
(288;291;292). Type I collagen fibers, the basic building block of the bone protein matrix 
network, are packed together to form collagen fibrils, arranged in a three-dimensional concentric 
weave in bone (293;294). Their mechanical strength depends on a highly regulated mechanism of 
intermolecular cross-linking that improves bone’s toughness or capacity to absorb energy (288). 
These collagen cross-links can be formed enzymatically (295-299) and by glycosylation or 
oxidation induce the formation of AGE’s (291;300).  
The mechanical effects of a collagen defect are most evident in diseases such as osteogenesis 
imperfecta (OI), where mutations in the type I procollagen gene leads to a marked increase in risk 
of fracture. 
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In contrast, the accumulation of excessive AGE cross-linking within collagen fibers is thought to 
deteriorate the mechanical function of bone (301). In vitro the cross-links are mediated by 
nonenzymatic glycation of bone collagen which is highly correlated with the stiffness of the 
organic matrix of bone (291). In turn, the increased stiffness of the organic matrix has been 
shown to reduce measures of collagen deformation and microcracking (291). Bone derives its 
resistance to fracture from collagen deformation (302) and from its ability to form microcracks 
during crack propagation (303). Collagen deformation and microcracking are the primary 
mechanisms of toughening in bone (304). Therefore, it is likely that in vivo accumulation of 
nonenzymatic glycation cross-links in collagen (305;306) may explain the loss of bone toughness 
based on a stiffer collagen network and loss of the collagen and micro-crack-based toughening 
mechanisms.  
The formation and accumulation of AGE’s occurs with aging at a constant but slow rate (307-
309). This process is remarkably accelerated in type 2 diabetes due to the increased availability of 
glucose (310). The AGE, pentosidine, has been shown to accumulate within collagen fibers in 
senescence as a result of glycation and oxidation. The result of pentosidine accumulation is 
decreased mechanical properties of bone, in response to the reduction of collagen fiber elasticity 
(287;288;296). This effect was demonstrated by Saito et al. (311) in animals when comparing the 
bone content of pentosidine in non-diabetic Wistar rats to the spontaneously diabetic WBN/Kob 
rats. The Wistar rats served as age-matched controls and exhibited gradually increasing 
pentosidine accumulation in the bone with age, while the WBN/Kob rats increased pentosidine 
only after the onset of diabetes. Three-point bending test demonstrated the WBN/Kob rats 
experienced further reduction of cortical bone mechanical properties when compared to the 
subclinical diabetic stage. The compromise in bone biomechanical properties in the WBN/Kob 
rats occurred with no significant decrement in BMD (311). A similar decrease in bone 
biomechanical properties was reported in a study by Verhaeghe et al. (312) where diabetic 
27 
 
animals experienced a decrease in bone strength and toughness, and increased stiffness compared 
to the control cohort. Importantly, these changes in biomechanical properties were observed 
without a significant decrease in BMD or bone mineral content (BMC) (312).   
Assessment of Bone Strength in Humans 
Results of mechanical tests in humans are limited due to the invasive nature of some procedures, 
but promising techniques including microindentation and nanoindentation are under development.  
Although outcomes remain to be validated, the former represents a first step toward in vivo 
characterization of tissue material properties. Other advantages include the relative ease of testing 
and the ability to make measurements in multiple locations within the tissue. A disadvantage of 
this technique is that its sole outcome is the tissue hardness (310). Nanoindentation advantages 
include the capability to measure the material properties of microstructural features such as 
lamellae (314;315) and to detect localized changes in bone material properties induced by disease 
or drug treatment (316).  
Continued advances in mechanical assessment will only bolster a growing scientific interest in 
bone health. Furthermore, accumulating evidence highlights the need for a closer examination of 
the deleterious effects of diminishing bone quality to better understand the compromise in bone 
strength associated with type 2 diabetes.  
Type 2 Diabetes and Bone Metabolism 
Although patients with type 2 diabetes do not necessarily show a reduction in BMD, fracture risks 
are known to increase compared to their non-diabetic counterparts (27;30;317). The increase 
however occurs with duration and has shown to present approximately 10 years post-diagnosis 
(7;8;284;285). Though the exact mechanisms responsible for this alteration in metabolism remain 
in question, there are many factors that, over time, contribute to the uncoupling of bone formation 
and resorption and consequently to the pathogenesis of fractures. Among these factors are the 
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effects of chronic inflammation (5) and AGE accumulation on osteoclasts and osteoblasts, the 
result of which lead to poor bone quality and impaired micro and macroarchitecture (318). In 
addition, insulin has been reported to exert an effect on bone metabolism (319).  
As previously mentioned, the diabetes-induced proinflammatory mediators TNF-α and IL-6 effect 
bone metabolism. One effect of IL-6 is through stimulation of osteoclast-induced bone resorption 
(228). An indirect effect utilizes the RANK/RANKL/OPG interaction on osteoclasts which 
promotes activation and subsequent bone resorption. The interaction is thought to be between IL-
6 and osteoblasts, and results in an increased osteoblastic RANKL production (231). The 
influence of TNF-α is demonstrated through increased osteoclastogenesis, decreased 
osteoblastogenesis and induction of vitamin D resistance (251). These effects are potent stimuli 
for bone loss that ultimately lead to deterioration of bone microarchitecture and increased fracture 
risk (253-257). 
The accumulation of AGE’s in diabetic conditions is a key mechanism involved in the induction 
of oxidative stress via reactive oxygen species (ROS) (310). AGE’s bind to AGE receptor 
(RAGE) which results in the generation of intracellular ROS through a nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase. The result of the increased ROS production on bone is 
seen in the inhibition of osteoblastic differentiation, increased osteoblast apoptosis and enhanced 
osteoclast activity (320). Mody et al. (321) demonstrated the influence of oxidative stress on 
osteoblast differentiation and activity using xanthine/xanthine oxidase (XXO) or hydrogen 
peroxide (H2O2) in a pre-osteoblast cell line ( i.e. MC3T3-E1) and a bone marrow stromal cell 
line ( i.e. M2-10B4). The pro-oxidants inhibited differentiation of osteoblasts, as assessed by their 
effect on alkaline phosphatase, a marker of osteoblast activity,  reduced mineralization (321) and 
induced osteoblast DNA damage and apoptosis via activation of caspase-3 (322;323).   
29 
 
Results presented by Cortizo et al. (324) indicated that exposure of osteoblast-like cells to AGE 
modified proteins that regulate the expression of RAGE. Although RAGE was found to be 
expressed in all stages of osteoblastic development, it was only observed to regulate activation of 
extracellular signal-regulated kinases (ERK) at the later stages of development, when osteoblasts 
had matured. When mature MC3T3E1 osteoblasts were cultured 1–3 weeks in continuous contact 
with AGE-collagen to assimilate a chronic AGE’s/RAGE interaction, the AGE’s decreased 
osteoblastic ERK activation which was associated with a decrease in both cell survival and 
calcified nodule formation (325).  
In addition to the effects on the osteoblast, oxidative stress has also been associated with 
enhanced bone resorption (326). Jagger et al. (327) recently reported that ROS may not increase 
in vivo bone resorption directly but rather indirectly by stimulating TNF-α expression. They 
suggest that ROS might augment osteoclast formation by directly acting on the intracellular 
signaling systems responsible for increased osteoclast formation.  
Results of in vitro insulin analysis demonstrate an effect on bone metabolism as well. Reports of 
both decreased resorptive activity of osteoclasts and inhibition of osteoblast apoptosis in the 
presence of insulin have been documented (328-330). Insulin action on bone may involve direct 
signaling through the insulin receptor, activation of bone anabolic IGF-1 signaling by binding to 
IGF-1 receptor, or synergistic effects with other anabolic agents such as parathyroid hormone 
(PTH) (330;331). The role of insulin on bone metabolism is important due to the state of 
hyperinsulinemia experienced in the early onset of type 2 diabetes (332-334).  
Native Americans and Osteoporosis Risk 
To date, the majority of the osteoporosis-related research has focused on Caucasian populations 
with limited information available on other high risk ethnic groups such as Native Americans 
(335) and Canadian Aboriginals (336). The First Nations Bone Health Study (336) was performed 
30 
 
in Canada to determine whether racial differences in body composition affect differences in BMD 
between Canadian White and Aboriginal women. Differences in BMD were not found between 
the two groups which left the question regarding the high fracture risk reported in Aboriginal 
women unanswered. The authors of the study indicated that there were several limitations, 
including a relatively small cohort and the study was underpowered for conducting age-specific 
analyses. Two large scale studies with relatively small Native American representation are the 
National Osteoporosis Risk Assessment (NORA) Study (34) and the Women's Health Initiative 
(WHI) Study (35). The purpose of NORA was to describe the relationship of BMD and 1-year 
fracture risk in a cohort of postmenopausal women of varied racial background. Findings from 
this study indicated that Native American’s risk for osteoporosis is at least as great as their 
Caucasian counterparts. The data also revealed a self-reported fracture history of 15.3% among 
Native Americans, the highest group percentage in the cohort (34). The WHI Study was designed 
to compare BMD and determine differences between postmenopausal Native American and white 
women. Wampler and colleagues (35) found that mean total hip, spine, and whole body BMD’s 
of Native American and white women were similar after controlling for age and BMI.  
Limited information is available relative to the prevalence of osteoporosis, rate of bone loss and 
the influence of lifestyle factors in this population. Several risk factors, characteristic of Native 
Americans, contribute to a possible explanation as to why they may be considered at high risk for 
osteoporosis or increased fracture. Obesity is a significant health issue among Native Americans 
who have a 1.6 times greater likelihood of obesity than Non-Hispanic whites. According to the 
Centers for Disease Control (CDC) in 2007, the age-adjusted percentage of Native American 
persons 18 years of age and over who were obese (i.e. BMI of > 30) was 33.2% compared to 
24.8% of whites (337), and the prevalence of obesity continues to increase (338). This 
observation was supported by data from the WHI Study where obesity (BMI > 30 kg/m2) was 
twice as prevalent in Native American women (50%) than in non-Hispanic white women (25%) 
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(35). Another contributing factor in the Native American community affecting bone health is low 
serum vitamin D (33). An individual’s vitamin D status depends mostly on exposure to sunlight 
and to a lesser extent on dietary intake of vitamin D. The synthesis of vitamin D by skin exposed 
to sunlight varies considerably due to factors such as skin pigmentation (339). Darker skin 
pigmentation results in lower cutaneous synthesis of cholecalciferol (339). This may contribute to 
findings by Perry et al. (33) of a decreasing serum 1,25-(OH)2D with increasing age in Native 
American women (33). A limited intake of dairy products, secondary to lactose malabsorption, 
may also exacerbate decreased serum vitamin D. Although the vitamin does not naturally occur in 
dairy products, it is a primary dietary food source due to its fortification. A study by Johnson et 
al. (340) demonstrated a 93% prevalence rate of lactose malabsorption among Native Americans 
(340). Vitamin D insufficiency has also been associated with diabetes (341). This becomes an 
important factor when considering Native Americans are a high-risk population for type 2 
diabetes (9). 
Statistics regarding Native American’s risk for type 2 diabetes are alarming. Data from the 2005 
IHS user database report 16.5% of the total adult population served by IHS had diagnosed 
diabetes (9). This is compared to 6.6% prevalence in non-Hispanic whites 20 years and older 
according to 2004–2006 national survey data (141).  
Given the prevalence of type 2 diabetes (9), obesity (337) and decreased vitamin D status (33) in 
the Native American population, there is sufficient evidence in support of a thorough examination 
of these factor’s and their metabolic impact on bone loss. The limited information available in 
this population imposes a daunting task to obtain basic knowledge of BMD, bone metabolism and 
inflammation for a better understanding of their association to bone health.  
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CHAPTER III 
 
 
METHODOLOGY 
 
Research Design   
This study was a longitudinal, causal-comparison design examining the extent to which type 2 
diabetes alters bone density and metabolism in Native American women. Outcome measures 
were obtained at two time points (baseline and at one year follow-up or final visit) to examine 
changes occurring in bone formation, bone resorption and BMD between type 2 diabetics and 
non-diabetics that may have resulted from inflammatory processes. This subset of a larger, two 
year study to examine the incidence of osteoporosis in Native Americans, included those 
participants completing the first two visits (n=123). Only Native American women, defined by 
their eligibility to receive services at an Indian Health Clinic, who were 50 years of age or older 
and committed to all study visits, were included. Excluded from the sample due to the weight 
limitations of the DXA instrumentation were those whose body weight was 300 pounds or 
greater. Pregnant women, as determined by urine pregnancy test, were also excluded due to risk 
of radiation exposure to the embryo/fetus.   
Participant recruitment involved a collaborative effort between the General Clinical Research 
Center’s (GCRC) Special Populations Core and area Indian Health Clinic’s medical treatment 
teams including physicians, nursing and auxiliary staff. The IHS clinics were provided 
information regarding the research study and were requested to inform eligible patients about 
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the opportunity. In addition, the clinics agreed to post research flyers and assist interested 
participants in contacting the GCRC. Potential participants contacted the GCRC to schedule an 
appointment and receive initial instruction regarding participation. Follow-up visits were 
scheduled via telephone calls and email if requested by the participant. Follow-up visits were 
analogous to baseline and procedures performed at baseline (i.e. DXA scan, relevant medical 
history and anthropometric measures) were repeated. Serum samples collected at each visit were 
processed and stored for batch measures of indicators of bone metabolism (e.g. bone specific 
alkaline phosphatase and C-telopeptide), 25-hydroxy vitamin D3, and inflammatory mediators 
(e.g. TNF-α and IL-6).   
All participants were encouraged to return to their respective clinics to discuss the results of their 
screening with their primary care physician.   
The study was approved by the Institutional Review Board (IRB) of the University of Oklahoma 
Health Sciences Center, IRB#13281 in reciprocal agreement with the Oklahoma State University 
IRB #HE0840 and Indian Health Services IRB #P-07-03-OK.   
Data collection  
Upon arrival, informed consent was obtained and participants were asked about their tribal 
heritage and categorized by blood quantum (bq): bq1 represents <50%, bq2 represents 50-100% 
(where bq=100% is a full blood Native American). Relevant medical history and anthropometric 
measures were collected by the nursing staff. In consideration of cultural diversity, the blood 
draw was designated optional for participation and required specific selection on the subject 
consent.  
Medical History and Supplement Use:  Information obtained included medical history and 
medication and supplement use. The same form was used at the final visit to identify changes that 
may have occurred over time.   
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Anthropometric Measurements:  Height and weight were measured at both visits. The protocol 
for assessing anthropometric measurements was adopted from the NHANES III survey. Waist 
and hip circumference were also measured to evaluate waist-to-hip ratio.   
DXA Evaluation of Bone Density and Body Composition:  The DXA measurements of each 
subject included the lumbar spine (L1-L4), hip, forearm, and whole body scans using a 
HOLOGIC 4500QDR/Delphi instrument (HOLOGIC, Inc., Waltham, MA). Available software 
calculates BMD (gm/cm2) by dividing BMC (in grams of calcium hydroxyapatite) by the area 
(cm2) of interest. Specific criteria for positioning subjects and for scan analysis were followed 
according to guidelines set forth by HOLOGIC. Instrument calibration, maintenance, and quality 
control were strictly maintained. All DXA scans were performed by the same certified bone 
densitometrist.   
Serum Biomarkers and Complete Blood Count (CBC):  Participants were presented the option of 
providing a blood specimen for serum analyses of inflammatory mediators, indices of bone 
metabolism, 25 (OH) vitamin D3, as well as an aliquot of whole blood for a CBC. Venous blood 
was collected at baseline and follow-up visits. Serum was separated within two hours of 
collection and aliquots stored at -80°C until the time of analysis. 
Serum bone-specific alkaline phosphatase (BAP) was measured as an indicator of bone formation 
using commercially available enzyme immunoassay (EIA) kits (MicroVue, Quidel Corporation, 
San Diego, CA). Intra-assay coefficients of variation (CV) were 5.8%, 3.9%, and 5.2% at low, 
medium, and high concentrations, respectively. Inter-assay CV’s were 5.2%, 7.6%, and 5.0% at 
low, medium, and high concentrations, respectively. 
Serum CTX was measured as an indicator of bone resorption using a commercially available 
ELISA assay (Immunodiagnostic Systems Inc. UK). Intra-assay CV’s were 3.0%, 1.7%, and 
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1.8% at low, medium, and high concentrations, respectively. Inter-assay CV’s were 10.9%, 9.7%, 
and 2.5% at low, medium, and high concentrations, respectively. 
Alterations in vitamin D status were assessed by measuring serum 25(OH)D3 using commercially 
available EIA kits (Immunodiagnostic Systems Inc. UK). The intra-assay CV’s were 5.3%, 5.6%, 
and 6.7% at low, medium, and high concentrations, respectively. Inter-assay CV’s were 4.6%, 
6.4%, and 8.7% at low, medium, and high concentrations, respectively. 
To examine the effects of inflammatory mediators, serum TNF-α and IL-6 were assessed. Serum 
IL-6 was measured using an ultra-sensitive sandwich-type ELISA assay (R&D Systems, 
Minneapolis, MN). The intra-assay CV’s were 6.9%, 7.8%, and 7.4% at low, medium, and high 
concentrations, respectively. Inter-assay CV’s were 9.6%, 7.2%, and 6.5% at low, medium, and 
high concentrations, respectively. 
Serum TNF- α was measured by an ultra-sensitive ELISA sandwich assay (R&D Systems, 
Minneapolis, MN). Intra-assay CV’s were 8.5%, 4.3%, and 3.1% at low, medium, and high 
concentrations, respectively. Inter-assay CV’s were 10.6%, 7.3%, and 7.4% at low, medium, and 
high concentrations, respectively.  
A CBC, including total white cell counts and differentials were performed on fresh, whole blood 
samples to investigate the relationships between total and differential white cell populations, 
osteoporosis risk and inflammation. 
Data analysis 
The data were analyzed using SAS version 9.2 (SAS Institute, Inc., Cary, NC). Descriptive 
statistics were calculated for all variables in individuals with and without type 2 diabetes, 
stratified by duration of diabetes diagnosis (<10 or ≥10 years) and included means and standard 
errors. A gamma statistic was used to determine frequency of osteopenia and osteoporosis at the 
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hip, spine and forearm sites in the population. Analysis of variance (ANOVA) was performed to 
detect differences between groups at baseline and final time points and change in measures of 
BMD, bone resorption and formation biomarkers, inflammatory markers and vitamin D status, 
followed by pair-wise comparisons. Primary outcome variables of interest were change in BMD 
observed from baseline, in the lumbar spine, hip and forearm. The secondary or explanatory 
outcome variables were biochemical markers of bone formation and bone resorption (i.e. BAP 
and CTX), inflammatory mediators (i.e. TNF-α and IL-6) and vitamin D status. Covariates 
including age and blood quantum were considered. Pearson correlation analyses were performed 
among the dependent and independent variables (e.g. vitamin D status vs. change in BMD). For 
all analyses, alpha was set at 0.05 for statistical significance. 
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CHAPTER IV 
 
 
  FINDINGS 
 
Description of the Study Population 
In this longitudinal study, 123 Native American women completed a baseline and final visit. 
Baseline characteristics of participants without a previous diagnosis of type 2 diabetes (non DM) 
and those with a previous diagnosis of type 2 diabetes mellitus (all DM) can be found in Table 1. 
Additionally, the all DM group is shown when stratified by years post diagnosis as either < 10 
years (DM< 10) or ≥ 10 years (DM≥ 10) due to the potential for increased risk of fracture with 
longer diabetes duration. Mean participant age for the non DM and the all DM groups was 61.02 
± 1.02 and 63.01 ± 1.06 years, respectively and did not differ from one another. A comparison of 
years post menopause between groups also found no differences. When the diabetics were 
stratified by duration of diabetes, there remained no differences between groups in mean age, an 
unexpected outcome, as longevity of diagnosis may assume an advanced age. Not surprising 
however, were the anthropometric measures that were significantly higher in the all DM group, 
including weight, BMI and waist/hip ratio (WHR). Although these measures were not 
unexpected, they are relevant to this study due to the effects of weight-bearing on bone and 
chronic inflammation associated with obesity, especially increased central adiposity. The BMI 
results demonstrate that though the non DM group was categorically overweight (i.e., 25-29.9), 
the BMI of the all DM group was still higher and considered clinically obese (i.e., ≥ 30). Not only 
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Table 1. Baseline Descriptive Characteristics of Groups According to Diabetes Mellitus (DM) Status. 
 Non DM1 
 (n=79) 
All DM2a   
(n=44) 
DM<103           
(n=19) 
DM≥104        
 (n=21) 
P 
(1vs2) 
P 
(1vs3vs4) 
Age (years) 61.02±1.02 63.01±1.06 63.2±1.63 61.8±1.47 0.210 0.601 
Years Post Menopause 14.2±1.30 15.5±2.0 16.2±2.3 14.1±3.6 0.560 0.788 
Smokingb (%) 23±5 26±7 39±12 15±8 0.679 0.212 
Packs/day 0.60±0.12 0.59±0.12 0.54±0.13 0.57±0.43 0.976 0.962 
Anthropometrics       
Height (cm) 163±0.67 160.7±0.92 160±1.52 161.8±1.33 0.051 0.160 
Weight (kg) 74.9±1.70 88.8±2.22 86.6±3.88 91.7±2.68 <0.001 <0.001*† 
Body Mass Index 28.2±0.62 34.5±0.90 33.9±1.6 35.1±1.1 <0.001 <0.001*† 
Waist/hip ratio 0.87±0.01 0.91±0.01 0.91±0.01 0.92±0.02 0.002 0.003*† 
Trunk fat (kg) 15.8±0.68 20.9±0.95 20.6±1.71 21.3±1.11 <0.001 <0.001*† 
Body fat (kg) 33.2±1.09 35.1±1.82 35.0±3.26 35.0±2.34 0.333 0.675 
Body lean (kg) 44.1±0.71 44.8±0.99 44.1±1.57 45.2±1.45 0.567 0.786 
Daily Calcium intake        
From food (mg) 974±63 811±56 902±84 755±80 0.082 0.195 
From supplements (mg) 450±83 410±101 630±206 227±81 0.762 0.152 
Total (mg)  1266±101 1126±109 1392±198 939±121 0.372 0.176 
Blood Quantum by DM Categoryc 
1= <50% 
2= ≥50% 
35±0.05 
n=52 
n=27 
64±0.07 
n=16 
n=28 
53±0.12 
n=9 
n=10 
76±0.10 
n=5 
n=16 
0.002 0.003† 
Data presented as mean ± SE unless otherwise noted. 
Non diabetic = non DM, all diabetic group = all DM, DM<10 = diagnosed diabetes <10 years, DM ≥10 = diagnosed diabetes ≥10 
years 
a
 Diabetes duration unknown in 4 participants.  
b
 Data presented as percent use ± SE. 
c
 Data presented as percent of participants categorized as BQ 2 (≥50%), ± SE, within each DM category. 
* Denotes statistically significant differences (ANOVA, p<0.05) between non DM and DM<10 
† Denotes statistically significant differences (ANOVA, p<0.05) between non DM and DM≥10
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were there differences in weight and BMI between the all diabetic and non-diabetic groups, but 
the distribution of weight differed as well. This was demonstrated by the WHR which showed the 
increase in the deposition of adipose tissue in the abdominal region compared to the hips. This 
was further supported by a significantly greater amount of trunk fat in the all DM group when 
compared to the non DM. Also expected, these anthropometric differences remained following 
the stratification of the all DM group by diabetes duration.  
Apart from anthropometric measurements, few baseline differences existed between groups 
despite comparisons of mean calcium intake and smoking predilection. One notable difference 
however, was blood quantum (BQ). That is to say, a greater number of individuals with a higher 
percent BQ were in the all DM group compared to the non DM group with 28 of the 44 
participants (64%) at BQ ≥50% (p=0.002). When the all DM group was stratified by duration, the 
difference remained and 16 of the 21 participants (76%) in the DM≥10 were BQ ≥50%. 
Results of a self-reported medical history questionnaire demonstrated few significant differences 
between non DM and all DM groups (Table 2). This included medications such as 
bisphosphonates and hormone replacement therapies which can have beneficial effects on bone as 
well as fracture history and previous osteoporosis diagnosis. Although no significant differences 
existed between the non DM and all DM groups in terms of fracture history report, when the all 
DM group was stratified by diabetes duration, the self-report of vertebral fracture incidence was 
significantly higher in the DM<10 than either the non DM or DM≥10 groups (p=0.021). As 
anticipated, thiazolidinedione (TZD) use was significantly higher in the all DM group than the 
non DM group (2% vs11% p=0.039) and this medication has been shown to have a deleterious 
effect on bone. Comparisons of the frequency of osteoporosis between groups based on WHO T-
score classifications the hip, spine and forearm, demonstrate that there was no significant 
difference in the prevalence of osteoporosis due to diabetes or duration of diabetes at any of the 
sites (Table 3). These data do suggest a discrepancy between self-reported osteoporosis and  
40 
 
 
Table 2. Self-Reported Osteoporosis Diagnosis, Fracture History and Medication Use of Groups by DM Status at Baseline. 
 Non DM1 
(n=79) 
All DM2a   
(n=44) 
DM<103           
(n=19) 
DM≥104         
(n=21) 
P 
(1vs2) 
P 
(1vs3vs4) 
Osteoporosis Diagnosisb 11±0.04 16±0.06 11±0.07 14±0.08 0.479 0.922 
Fracture Historyb       
Vertebral fracture 3±2 7±4 16±9 0 0.259 0.021*‡ 
Hip fracture 3±2 0 0 0 0.291 0.604 
Medication Usec       
Bisphosphonate 8±0.03 5±0.04 12±0.08 0 0.654 0.393 
Hormone Replacement Therapy  15±0.04 13±0.06 12±0.08 18±0.10 0.783 0.893 
Thyroid hormone  26±0.05 32±0.08 24±0.11 35±0.12 0.528 0.695 
Selective Estrogen Receptor  
(SERMs) 
3±0.02 0 0 0 0.283 0.599 
Thiazolidinedione’s (TZDs) 2±0.02 11±0.05 6±0.06 18±0.10 0.039 0.024† 
Selective Serotonin Reuptake 
Inhibitors (SSRIs) 
26±0.05 21±0.07 18±0.10 24±0.11 0.593 0.788 
Non diabetic = non DM1, all diabetic group = all DM2, diagnosed diabetes <10 years = DM<103, diagnosed diabetes ≥10 years = DM 
≥104 
a
 Diabetes duration unknown in 4 participants.  
b
 Data presented as percent occurrence, ± SE. 
c
 Data presented as percent use, ± SE. 
* Denotes statistically significant differences (p<0.05) between non DM and DM<10 
† Denotes statistically significant differences (p<0.05) between non DM and DM≥10 
‡ Denotes statistically significant differences (p<0.05) between DM<10 and DM≥10 
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Table 3. Frequency of Osteopenia and Osteoporosis of the Hip, Spine and Forearm by Diabetes Status. 
 
Non DM1 
(n=74) 
All DM2 
(n=38) 
DM<103 
(n=17) 
DM≥104 
(n=21) 
P 
(1vs2) 
P 
(1vs3vs4) 
Classification by  
T-scorea N O Op N O Op N O Op N O Op 
  
Total Hip 47 24 3 28 9 1 13 3 1 15 6 0 0.554 0.643 
Total Spine 48 22 4 25 12 1 11 6 0 14 6 1 0.793 0.896 
Total Forearm 24 38 12 14 15 9 7 4 4 7 9 5 0.441 0.750 
Non diabetic = non DM1, all diabetic group = all DM2, diagnosed diabetes <10 years = DM<103, diagnosed diabetes ≥10 years = DM 
≥104 
a
 Classification by T-score defined by the World Health Organization: 
   N = normal (> -1 standard deviation below the mean); 
   O = osteopenia (between -1 and -2.5 standard deviations below the mean); 
   Op = osteoporosis (< -2.5 standard deviations below the mean)
  
Figure 1. BMD of the total hip, intertrochanter, trochanter and femoral neck 
regions of the hip. Comparisons were made between non 
diabetic (All DM) groups at baseline and final visit. 
* indicates statistically significant difference (p<0.05)
 
osteoporosis observed in this study. The frequency of T
than identification by the participants, most notably in the forearm.
Bone Densitometry  
Results of DXA measurements revealed
DM and all DM groups (Figure 1)
to the non DM group at both time points in the intertrochanter and at the final 
hip. In contrast, no significant differences in BMD were observed in either the 
distal forearm (Figure 2). Differences in BMD between groups can often be explained by 
alterations in BMA and/or BMC
measures at the intertrochanter or total hip at either time point
42 
diabetic (Non DM)
Bars indicate mean ± SE 
 between groups
-scores in the osteoporotic range is greater 
 
 significant differences in the hip region
. BMD was significantly higher in the all DM 
visit in the total 
lumbar 
, but no significant differences were observed in either of these 
 in this study (Appendix A
 and all 
and     
.  
 between the non 
group compared 
spine or 
). This 
 Figure 2. BMD of the total 
made between non diabetic (Non DM)
and final visit. No statistically significant differences (p<0.05) were 
between non DM and all DM groups at either time point
 
observation suggests that modest changes in BMA and BMC were likely responsible for the 
significant change in BMD. 
all DM group was stratified
DM<10 group compared to the non DM and DM 
intertrochanter and total hip sites. Stratification also revealed a significantly higher BMD in the 
trochanter region in the DM<10 
statistically significant differe
stratification by duration of diabetes diagnosis
BMD differences between groups observed at the
trochanter) were not altered, but the increase in femoral neck BMD in the 
compared to the non DM and DM 
(p=0.035) (data not shown)
43 
lumbar spine and distal forearm. Comparisons were 
 and all diabetic (All DM) groups at baseline 
observed 
. Bars indicate mean ± SE.
To examine the effects of diabetes duration on BMD in the hip, the 
 (Figure 3). A significantly higher BMD value was observed in the 
≥10 groups in the final visit at both the 
group compared to the non DM and DM ≥10 groups. No 
nces were noted in either the lumbar spine or forearm with 
. When adjustments were made for age and BQ, 
 hip (i.e., total hip, intertrochanter and 
DM < 10 group 
≥ 10 groups did reach a level of statistical significance 
.   
 
the 
 Figure 3. BMD values of total hip, intertrochanter and trochanter at final visit. 
Comparisons were made between non 
years duration from diagnosis (
diagnosis (DM≥10) groups. 
differences (p<0.05) denoted 
 
Based on the usefulness of the WHO classifications of T
(17), it is important to note that both total hip 
greater in the all DM group at both time
same group at the final visit.
for all groups (i.e., non DM, all DM,
(i.e., T-score <-1.0) at both 
and BQ as well. Findings in the lumbar spine more closely resembled those of the forearm than 
the greater weight-bearing sites of the hip in that no significant differences 
between any of the groups. 
DXA results at each site were
only statistically significant 
44 
diabetic (Non DM), diabetic less than 10 
DM<10) and diabetic 10 years or greater post
Bars indicate mean ± SE and statistically significant 
*. 
-scores as an indicator of fracture risk 
and intertrochanter T-scores were significantly 
 points as was the femoral neck T-score greater in the
 Results of the forearm measures actually showed the mean T
 DM<10, and DM≥10 groups) to be in the osteopenic range
baseline and final visits. Results were similar when adjusted for age
in T
 also analyzed to assess percent change over time 
differences noted were the increased rate of change 
 
-
 
-score 
 
 
-scores existed 
(Table 4). The 
in the all DM  
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 Table 4. Percent Change in Bone Mineral Area, Content, Density and T-scores from Baseline to Final Visit According to 
Diabetes Status. 
 Non DM1 
 (n=79) 
All DM2a   
(n=44) 
DM<103          
 (n=19) 
DM≥104  
(n=21) 
P  
(1vs2) 
P 
(1vs3vs4) 
Total Hip       
BMA  1.005±<.004 1.011±0.007 1.019±0.012 1.006±0.007 0.239 0.318 
BMC  1.012±0.006 1.009±0.010 1.030±0.019 0.994±0.010 0.952 0.259 
BMD  1.007±<.004 1.033±0.036 1.088±0.078 0.988±0.007 0.688 0.024*‡ 
T-score                1.012±0.088 0.952±0.132 0.757±0.151 1.163±0.239 0.640 0.338 
Intertrochanter       
BMA  1.015±0.009 1.021±0.014 1.034±0.025 1.017±0.017 0.717 0.686 
BMC  1.023±0.010 1.019±0.015 1.047±0.028 1.003±0.016 0.859 0.328 
BMD  1.008±0.004 1.018±0.030 1.074±0.062 0.970±0.019 0.669 0.022*‡ 
T-score                1.070±0.065 0.940±0.159 0.980±0.224 0.906±0.268 0.373 0.676 
Total Spine       
BMA  0.999±0.003 1.001±0.006 0.992±0.010 1.008±0.010 0.534 0.150 
BMC  0.999±0.005 1.003±0.009 0.995±0.016 1.014±0.012 0.454 0.241 
BMD  0.999±0.004 1.003±0.005 1.005±0.009 1.006±0.007 0.488 0.600 
T-score 1.023±0.120 0.699±0.136 0.526±0.272 0.815±0.122 0.090 0.146 
Forearm       
BMA  1.004±0.002 0.997±0.003 0.994±0.005 1.001±0.004 0.026 0.085 
BMC  0.994±0.003 0.989±0.004 0.994±0.007 0.988±0.006 0.162 0.217 
BMD  0.990±0.002 0.991±0.003 0.998±0.005 0.987±0.004 0.820 0.157 
T-score 0.999±0.124 1.019±0.114 1.020±0.034 0.877±0.219 0.921 0.881 
Data are presented as percent change ± SE. 
Non diabetic = non DM, all diabetic group = all DM, DM<10 = diagnosed diabetes <10 years, DM ≥10 = diagnosed diabetes ≥10 
years 
a
 Diabetes duration unknown in 4 participants. 
* Denotes statistically significant differences (p<0.05) between non DM and DM<10 
‡ Denotes statistically significant differences (p<0.05) between DM<10 and DM≥10 
 Figure 4. Percent change
over one year. Comparisons were made between non 
less than 10 years duration from diagnosis (
post-diagnosis (DM≥10)
significant differences (p<0.05) denoted 
 
group compared to the non DM group in the BMA of the forearm (p=0.026) and the femoral neck 
T-score (p=0.033) (data not shown
stratified by diabetes duration. An interesting observation resulting from the stratification was a 
change in BMD in the total hip and intertrochanter regions 
the DM<10 group was significantly 
and DM ≥10 groups. This result was not seen in the lumbar spine
Biochemical Markers of Bone Metabolism
Baseline and final visit comparisons of serum CTX were made to examine differences between
diabetics and non-diabetics and the effects of diabetes duration on bone resorption and bone 
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 in BMD of total hip and intertrochanter region of the hip 
diabetic (Non DM
DM<10) and diabetic 10 years or greater 
 groups. Bars indicate percent change ± SE and s
between*.  
). Both of these affects were lost when the all DM 
(Figure 4). Here the percent change in 
greater than the change observed in the BMD of
 or forearm. 
 
), diabetic 
tatistically 
group was 
 the non DM 
 
 formation. A significantly lower
non DM group at the baseline
stratification of the all DM group, a significantly lower concentration of CTX in the DM<10 
group compared to the non DM group (p=0.031) was observed. S
reached when assessing the 
(p=0.072) or when the all DM group was stratified by diabetes duration (p=0.295) (
shown).  
Figure 5. Serum C-telopeptide
and final visits. Comparisons were made between non 
diabetic (All DM), diabetic less than 10 years duration from diagnosis (
diabetic 10 years or greater post
denoted between Non DM and DM<
 
Serum BAP reflects osteoblast
Comparisons of serum BAP 
not different, nor did they differ following stratification of the all DM group 
diabetes diagnosis (Figure 
evaluated based on the percent change
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 serum CTX was observed in the all DM group compared to 
 (p=0.006), but not at the final visit (Figure 5). Following 
tatistical significance
percent change in CTX between the non DM and all DM groups 
 of type I collagen (CTX) concentrations at baseline 
diabetic (Non 
-diagnosis (DM≥10) groups. Significan
10 by *. Bars indicate mean ± SE.
 activity, and was therefore used as an indicator of
between diabetics and non-diabetics at baseline and 
by duration of 
6). Additionally, no differences were observed when 
 over time.  
the 
 was not 
data not 
 
DM), all 
DM<10) and 
ce (p < 0.05) 
  
 bone formation. 
final visits were 
serum BAP was 
 Negative correlations were observed in the all DM group between CTX and forearm
both time points but no significant relationship 
BMD at any site was noted.
Figure 6. Serum bone alkaline phosphatase (BAP) concentrations at baseline and 
final visit. Comparisons were made between non 
DM), diabetic less than 10 years duration from diagnosis (
years or greater post-diagnosis (
differences (p<0.05) were 
indicate mean ± SE.  
 
correlation was noted as a negative relationship b
the DM <10 group. These data indicate that the only site in which the anticipated negative 
relationship between bone resorption and BMD was observed was at the least weight
skeletal site. 
Cytokines and Complete Blood 
Results of the serum cytokine TNF
between the all DM and non DM groups, or when the all DM group was 
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in percent change between CTX and BAP and 
 When the all DM group was stratified by diabetes duration, a single
diabetic (Non DM), all
DM<10) and 
DM≥10) groups. No statistically significant 
observed between groups at either time point
etween CTX and forearm BMD at baseline in 
Count 
-α (Figure 7) assessment revealed no significant differences 
stratified by diabetes 
 BMD at 
 
 diabetic (All 
diabetic 10 
. Bars 
-bearing 
 Figure 7. Serum TNF-α concentrations at baseline and final visit for 
(Non DM), all diabetic (All 
(DM<10) and diabetic 10 years or greater post
statistically significant differences (p<0.05) were 
time point. Bars indicate mean ±
 
duration at either the baseline or final visit. In addition no observable differences in TNF
IL-6 were noted between groups wh
shown).When the cytokine IL
differences between the all DM and non DM groups, or when the all DM group was stratified by 
diabetes duration at either the baseline or final visits.
Lymphocyte percent was significantly lower in the all DM group compared to the non DM group 
at the final visit, but this effect was lost when the diabetic group was stratified
other differences in lymphocyte 
Monocyte absolute counts and percent were not different between any groups
note that all mean lymphocyte and monocyte counts
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DM), diabetic less than 10 years duration from diagnosis 
-diagnosis (DM≥10) groups
observed between groups at either 
 SE.  
en results were assessed for percent change (
-6 (Figure 8) was assessed, results again revealed
 
 (Table 
absolute counts or percent were observed between groups
. It is important to 
 were within normal limits. 
 
non diabetic 
. No 
-α and 
data not 
 no significant 
5). No 
. 
 
 Figure 8. Serum IL-6 concentrations at baseline
DM), all diabetic (All DM
(DM<10) and diabetic 10 years or greater post
statistically significant differences (p<0.05) were 
time point Bars indicate mean ±
 
The pro-inflammatory cytokines 
associated with a decrease in bone formation and increase in bone resorption that may ultimately 
lead to bone loss. A positive correlation between TNF
baseline in the non DM group but not in the all DM group
BAP and TNF-α was observed in either 
Positive correlations between BAP and CTX were noted in the non DM, all DM and DM<10 
groups at baseline, however, this was not the case
Somewhat unexpectedly, no correlations between metabolic markers were
DM≥10 group at either visit. 
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 and final visit for non
), diabetic less than 10 years duration from diagnosis 
-diagnosis (DM≥10) groups
observed between groups at either 
 SE. 
present in chronic disease such as diabetes have 
-α and CTX (p=0.005) was demonstrated at
 (Figure 9). No correlation between 
the non diabetic or all diabetic groups (data not shown)
 for the DM≥10 group (data not shown)
 identified in the 
 
-diabetic (Non 
. No 
also been 
 
. 
. 
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Table 5. Serum Markers of Inflammation, Lymphocyte and Monocyte Counts at Baseline and Final Visit According to 
Diabetes Status. 
 Non DM1 
(n=79 ) 
All DM2a 
(n= 44) 
DM<103           
(n= 19) 
DM≥104  
(n= 21) 
P  
(1vs2) 
P 
(1vs3vs4) 
Pro-inflammatory Cytokines      
Tumor Necrosis Factor 
(TNF)-α  
      
   Baseline (pg/mL) 1.54±0.11 1.59±0.10 1.46±0.11 1.7±0.18 0.733 0.619 
   Final (pg/mL) 1.47±0.08 1.55±0.08 1.49±0.11 1.58±0.14 0.609 0.873 
     Interleukin (IL)-6       
   Baseline (pg/mL) 2.48±0.42 3.64±0.55 3.0±0.59 4.6±1.02 0.102 0.088 
   Final (pg/mL) 2.88±0.33 3.85±0.77 3.0±0.45 4.9±1.6 0.171 0.096 
 
Blood Count Percent      
LYMPH        
   Baseline (%) 30.3±0.92 28.8±1.1 28.2±1.3 30±1.7 0.367 0.537 
   Final (%) 31.5±1.05 28.6±0.86 27.6±1.09 29.5±1.5 0.041 0.097 
MONO %       
   Baseline (%) 7.3±0.25 7.0±0.28 7.1±0.49 6.9±0.4 0.523 0.762 
   Final (%) 7.4±0.26 7.5±0.39 8±0.66 7.1±0.51 0.998 0.486 
 
Blood Count Absolute Counts 
LYMPH #       
   Baseline (µL) 1.95±0.07 2.04±0.12 1.9±0.13 2.2±0.22 0.537 0.358 
   Final (µL) 1.94±0.07 2.0±0.14 1.8±0.11 2.1±0.28 0.696 0.380 
MONO #       
   Baseline (µL) 0.47±0.02 0.48±0.03 0.44±0.04 0.51±0.05 0.773 0.473 
   Final (µL) 0.46±0.02 0.49±0.02 0.49±0.03 0.49±0.04 0.236 0.533 
Data presented as mean ± SE. Non diabetic = non DM, all diabetic group = all DM, DM<10 = diagnosed diabetes <10 years, DM ≥10 
= diagnosed diabetes ≥10 years. a Diabetes duration unknown in 4 participants. No statistical differences were found (p<0.05).
  
Figure 9. Correlation of CTX to TNF
all diabetic (All DM) group at baseline visit. 
observed in the Non DM group that 
correlations were evaluated by Pearson’s correlation coefficient.
 
Vitamin D 
Given vitamin D’s relationship with calcium homeostasis and bone metabolism, differences in 
serum 25-hydroxy vitamin D were examined between groups.
between any of the groups were noted at either time point 
of the non DM group and the DM<10, both groups’ vitamin D status exceeded 50 nmol/L, the 
serum value recommended by the Institute of Medicine (IOM) to sustain bone density, calcium 
absorption, and to minimize risk of osteomalacia and 
in this study did not reach recommended 
which suggests that the longer duration diabetic may be at greater risk for compromised vitamin 
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A significant positive correlation 
was not present in the All DM group. 
 
 No differences in serum vitamin D
(Figure 10). Based on the mean value 
rickets (342). However, the DM
serum 25-hydroxy vitamin D levels at either time point
 
) group and the 
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Linear 
 
≥10 group 
 
 status. Data from the Third 
demonstrate the national average serum 25
and diabetes (i.e., 63.4 nmol/L) (3
 
 
Figure 10. Serum 25-hydroxyvitamin D concentrations
all diabetic (All DM), diabetic less than 10 years from diagnosis (
diabetic 10 years or greater post
visits. For visual comparison, 
Examination Survey (NHANES III) 
(NHANES Ages 50-69) and NHANES III adults diagnosed with diabetes 
DM) are shown. The black vertical bar at 50 nmol/L 25
Institute of Medicine (IOM)
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- hydroxyvitamin D in similar age (i.e., 70.6 nmol/L) 
43) categories exceed that of the non DM and all DM groups.
 of non diabetic (Non 
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-diagnosis (DM≥10) groups at baseline and final
results from the Third National Health and Nutrition 
of adults 50-69 years of age from NHANES III 
-hydroxy vitamin D indicates 
 recommended serum levels. Bars indicate mean ±
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CHAPTER V 
 
 
DISCUSSION 
 
This study was designed to examine the effects of type 2 diabetes and diabetes duration on bone 
health in Native American women. It is important to note that this study was part of a larger study 
to examine the incidence of osteoporosis in Native American women over the age of 50 in the 
state of Oklahoma. BMD was the primary outcome variable in this study and represents a means 
of assessing fracture risk. 
The findings of this study demonstrate that BMD differences did occur between diabetics and 
non-diabetics and more specifically in the hip regions. This effect appears to be biphasic as BMD 
was increased in the hip region the first ten years following diagnosis and decreased in the same 
region, after the initial decade. Although greater rate of change in BMD in the DM group was 
anticipated, it was not expected to continue to increase. This demonstration of both greater BMD 
and increased rate of change in the DM<10 group suggests that detrimental metabolic changes in 
bone, specific to the hip regions, occurred at some point after the first decade following diabetes 
diagnosis. A possible explanation for this biphasic effect could be related to the compensatory 
hyperinsulinemia accompanying the onset of type 2 diabetes in an effort to lower blood glucose 
levels (332-334). The ability of insulin to stimulate collagen production by osteoblasts has been 
55 
 
well documented and the effect has been observed at physiological insulin concentrations 
(133;344-346).  
The increased BMD in the DM<10 group however, was characterized by no change in serum 
BAP and decreased serum CTX compared to the other groups which suggests that bone formation 
was constant while resorption was attenuated. This effect has been documented in transgenic L-
SACC1 mice with liver-specific overexpression of mutant of the Carcinoembryonic Antigen-
related Cell Adhesion Molecule 1 (CEACAM1). These mice have decreased CTX that was 
attributed to impaired insulin clearance. The resulting high levels of insulin in this animal model 
were shown to affect recruitment and differentiation of osteoclasts by impairing RANKL 
signaling (319). Although insulin was not measured in the current study, a similar impaired 
insulin clearance has been previously reported in type 2 diabetics (347;348)  
Over time a decline in β cell number and function results in decreased circulating insulin. This 
may explain the latter phase of this effect when BMD was reduced in the DM ≥10 longer duration 
diabetics and the rate of change returns to one more closely related to the non-diabetic group. 
With diabetes duration, the bone made dense by resorption impairment in the first decade is more 
likely to have structural irregularities affecting strength. This could be due in part to the 
accumulation of AGEs that have been observed in obese mouse models of type 2 diabetes and 
resulted in reduced bone strength (349). The alterations in BMD observed in the current study are 
in agreement with other studies conceding that the onset of increased fracture risk (8;285) and 
even fracture incidence (25;284) in type 2 diabetes occurs 10 years or more post-diagnosis. This 
has also been demonstrated specific to race in populations including Asian (350), Hispanic (351) 
and Norwegian (352;353) where results show that the risk of hip fracture was higher among 
people with diabetes than without and this risk increased with duration of diabetes diagnosis. 
Differences in self-reported fracture of the hip were not detected between groups in the current 
study, although participants were asked to respond to questions regarding fracture history. 
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Importantly, this study was not powered to evaluate fracture incidence and thus the absence of a 
difference between groups could be expected. Emerging evidence in studies powered to detect 
differences in fracture incidence however, has shown that patients with type 2 diabetes have 
higher fracture rates (1.4-fold) in spite of the absence of a reduction in BMD (30). This suggests 
that BMD values in diabetics, 10 years or longer, that are similar to non diabetics of a similar age 
group may not adequately reflect bone fragility.  
In this study, differences in BMD between groups were observed in the hip regions alone and 
could be attributed to this regions primary function of weight bearing. Weight was not considered 
as a covariate in the current study due to its influence on type 2 diabetes. The lumbar spine also 
has a role in weight bearing, but has been shown to respond to different forces than those applied 
to the hips. If differences in the hip were due to weight bearing influences, this would explain 
why forearm BMD’s were similar between groups.  
Although BMD remains a useful measurement for fracture prediction in the non-diabetic 
population, these findings suggest a need to clarify the use of standard methods for assessing 
fracture risk using BMD in type 2 diabetes due to biphasic effects of diabetes with duration.  
At this time it remains unclear exactly why BMD is not an accurate predictor of long-term 
fracture risk in the diabetic population. Animal studies using experimental models of diabetes 
have suggested that with diabetes duration bone structure is altered in a way that increases 
stiffness and compromise overall bone strength (291). This idea of compromised bone quality 
provides a possible explanation of the paradox of an increased risk of fractures in type-2 diabetics 
in the presence of normal or elevated BMD (354;355).  
Examination of the current findings revealed a significantly lower serum CTX in the DM<10 
group when compared to the non-diabetic group at some time points. It could be postulated that 
the lower concentration of CTX seen in the DM<10 group was responsible for the increased 
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BMD in the hip regions. Consensus has yet to be reached as to the explanation of the effects of 
diabetes on bone metabolism. Oz et al. (356) examined bone biomarkers in men and women, 
diabetic and controls and observed that the serum BAP and CTX in the diabetics were 
significantly lower than the non diabetic controls. When the same markers were evaluated 
according to gender, it was discovered that only CTX was reduced in the male diabetic population 
whereas the diabetic women experienced a reduction in BAP only. Other studies have reported 
significantly elevated BAP in type 2 diabetics over non diabetic counterparts (357-359). Bone 
biochemical markers have been shown to differ among ethnic groups (360), but no data is 
available to determine if differences exists among Native American populations. The bone 
biochemical marker data in this study suggest a decrease in bone resorption with no change in 
bone formation in the DM<10 group, but further examination of bone biochemical markers in 
Native American women is warranted. 
 
No differences between groups were observed in serum IL-6 or TNF-α. In addition, no 
correlations existed between markers of metabolism and cytokines in the diabetic groups. 
Although numerous factors can influence serum levels of these cytokines it is possible that the 
observed outcomes were an indication that mechanisms affecting bone metabolism in non-
diabetic models may not function the same in a diabetic environment. It is noteworthy that much 
of the research related to the effects of TNF-α and IL-6 have been demonstrated in non-diabetic 
models. An example of this influence of TNF-α on increased osteoclastogenesis, has been 
demonstrated in in vitro models (361;362), and with TNF-α infusion in normal (363;364) and 
nude mice (365). In addition to its effects on osteoclastogenesis, TNF-α also suppresses 
osteoblastogenesis as demonstrated in vitro (256-259) and in transgenic mouse models (366). A 
similar outcome was reported with IL-6 overexpression in transgenic mice resulting in increased 
osteoclast and decreased osteoblast number and activity (228). However, in all of these cases, the 
effects of TNF-α and IL-6 were reported in the context of a non-diabetic model. These examples 
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illustrate that less is known about the relationship between inflammatory mediators and bone 
metabolic processes in the diabetic. Based on observations such as the biphasic response of BMD 
in the hip in this study, it appears that type 2 diabetes potentially represents a unique scenario 
relative to bone metabolism. Therefore more research is required so that therapeutic approaches 
can be developed to prevent or reduce the number of fractures in this population. 
Identifying potentially modifiable risk factors for fracture in Native Americans with type 2 
diabetes is of major importance for future diabetes health care initiatives. Important to that task is 
exploring the metabolic differences and the factors that contribute to these differences. It is also 
important to consider outcomes from the current study in context of other published reports. For 
example, TNF-α has been shown to influence osteoclastogenesis, a finding supported by the 
positive correlation of CTX to TNF-α in the non-diabetics of the current study. However, this 
does not hold true in this diabetic population. It is also plausible that an inflammatory biomarker 
such as TNF-α may not be different between these groups due to innate differences among Native 
Americans. Reference standards, (e.g. T-scores) are often based on Caucasian populations (15;16) 
making race-related deviations conceivable, a concept evidenced in fact by the higher average C 
reactive protein (CRP) concentrations seen in this population (367). This non-diagnostic test is 
used for the detection of inflammation and must be compared to appropriate ethnic normative 
reference data to ensure relevance. In addition to the inflammatory markers, low serum vitamin D 
in Native Americans has been reported (33), but the mean serum concentrations of the diabetic, 
non-diabetic and the group as a whole in this study were within the current IOM 
recommendation. Results of the self-reported calcium intake did not differ between groups and 
should be examined as well as physical activity, specifically weight-bearing for greater 
understanding of the role they play specific to bone health in Native Americans. Perhaps further 
exploration into race-related norms is in order to determine the usefulness of standard measures 
and their role in chronic disease.  
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Currently patients with type 2 diabetes represent a diagnostic and prognostic dilemma because the 
value of BMD measurement in predicting osteoporotic fractures may be limited by decreased 
bone quality. Given the prevalence of type 2 diabetes in Native Americans, this population is at 
great risk. This necessitates exploration into underlying alterations in bone metabolism 
responsible for the biphasic response observed in this study and a greater understanding of the 
contributing risk factors. Improving understanding of the mechanisms involved will provide 
guidance toward better methods of assessment and treatment more appropriate than BMD may be 
discovered. It is necessary to recognize the need for not only different methods of risk assessment 
but different options of reducing risk as well. Therefore, evidence-based guidelines of fracture 
risk management, especially in Native Americans with diabetes are warranted.  
 
 
 
 
 
60 
 
CHAPTER VI 
 
 
CONCLUSION 
 
Summary 
Recent evidence suggests a relationship between type 2 diabetes and an increased risk of fracture. 
Native Americans are known to have a high prevalence of type 2 diabetes (i.e. ~2 times the 
national average), but the availability of evidence regarding fracture risk is limited in this 
population. This study was designed to examine the extent to which type 2 diabetes affects 
change in BMD and bone metabolism in Native American women. Participants included Native 
American women (n=123) 50 years of age and older, defined by their eligibility to receive 
services at an Indian Health Clinic. Of the total, 36% (n=44) reported a diagnosis of type 2 
diabetes to which the all DM group was stratified by years post-diagnosis due to the potential for 
increased risk of fracture with longer diabetes duration. Baseline and final visits included DXA 
scans to determine BMD, relevant medical history and anthropometric measures. In addition, an 
optional serum sample was collected for measures of bone metabolism indicators, 25-
hydroxyvitamin D3, and inflammatory mediators (e.g. TNF-α and IL-6).  
DXA results revealed increased BMD in the hip regions of the DM group and more specifically 
the DM<10 years duration group. In fact the stratification of the diabetes group by duration   
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supports the possibility of a biphasic effect evidenced by increasing BMD in the hip 
region the first 10 years post-diagnosis, followed by significant decreases in the same 
region after the first decade following diabetes diagnosis. No differences in BMD were 
observed in the spine or forearm regions. The only difference observed in bone metabolism was 
decreased CTX in the all DM group. No differences were observed between groups in 
inflammatory mediators or vitamin D concentrations. These findings suggest a need to clarify 
the use of standard methods for assessing fracture risk using BMD in type 2 diabetes due 
to biphasic effects of diabetes with duration. Additionally, mechanisms affecting bone 
metabolism in non DM models may not function similarly in a diabetic environment. The 
differences occurring over time between the stratified diabetes group, is a possible indication that 
mechanisms are modified with disease duration. Finally, it remains to be determined if 
differences in this study, or lack of differences, is due to innate differences within the Native 
American population. 
Purpose  
The purpose of this study is to examine the effects of type 2 diabetes and diabetes duration on 
bone health compared to non-diabetics in Native American women over 50 years of age.  
Hypothesis 1:  Change in BMD from baseline to final visit, one year later, will be greater in those 
women with type 2 diabetes and especially those women who have been diabetic for ten or more 
years compared to their non-diabetic counterparts. 
No statistically significant difference in percent change in BMD was observed between the non 
DM and all DM groups. When the all DM group was stratified by duration of DM diagnosis, 
however, the DM<10 group demonstrated a significantly greater increase in BMD in the total hip 
and intertrochanter regions compared to both the non DM and the DM≥10 groups. The DM≥10 
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group demonstrated a decrease in BMD compared to the DM<10 at the same sites. Therefore we 
rejected the null hypothesis based on the stratification of the DM group by diabetes duration. 
Hypothesis 2:  Type 2 diabetics will demonstrate alterations in bone metabolism consistent with 
increased bone resorption and decreased bone formation rates from baseline to final visit, 
compared to non-diabetics. These alterations in bone metabolism will be more pronounced in 
longer duration type 2 diabetics (i.e., > 10 yrs).     
No statistically significant difference in bone resorption or formation was observed between the 
non DM and all DM groups. When the all DM group was stratified by duration of DM diagnosis 
no differences were observed when compared to the non DM group. We failed to reject the null 
hypothesis.  
Hypothesis 3:  The mechanisms by which type 2 diabetics will experience accelerated bone loss 
will be mediated by an increased inflammatory state and compromised vitamin D status. The 
increased inflammatory state and compromise in vitamin D status will be exacerbated in longer 
duration diabetics. 
No statistically significant difference in the inflammatory mediators TNF-α or IL-6 was observed 
between the non DM and all DM groups. No statistically significant difference in serum 25-
hydroxy vitamin D was observed between the non DM and all DM groups. When the all DM 
group was stratified by duration of DM diagnosis no differences were observed when compared 
to the non DM group in either inflammatory mediator or serum 25-hydroxy vitamin D. We failed 
to reject the null hypothesis. 
Recommendations for Future Research  
As the prevalence of type 2 diabetes continues to rise, acknowledging the numerous 
complications and developing effective prevention and treatment strategies becomes increasingly 
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important. The recently discovered relationship between diabetes and bone introduces the 
increased risk of fracture as another complication that needs to be considered clinically. Important 
next steps will include exploration into factors affecting bone strength. This will require the use 
of animal models as well as techniques to determine alterations in bone biomechanical properties 
in humans. A better understanding of the influences of insulin and glucose control on biochemical 
markers of bone turnover is also needed. Impaired insulin clearance has been observed in type 2 
diabetes and recently been associated with decreased bone resorption. Monitoring insulin levels 
with disease progression, in conjunction with bone biochemical markers, may provide new 
insight into metabolic changes in bone over time. 
Another important point to consider is that the current literature focused on fracture risk and 
type2 diabetes only delineates type 2 diabetics by the number of years post-diagnosis. Other 
factors such as glucose control, the role of renal function and physical activity may also 
contribute to the ultimate effects of type 2 diabetes on bone health and fracture risk. Future 
studies should take these factors into consideration. 
Lastly, it will also be essential in this pursuit to identify differences inherent to specific 
populations. Relatively little is known about Native Americans and osteoporosis risk. Therefore it 
is important to establish population based norms for different ethnic groups not only for BMD but 
also biochemical markers of bone metabolism. 
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Appendix A. DXA Measurements of the Hip Regions at Baseline and Final Visit According to DM Status. 
 Non DM1 All DM2 DM<103 DM≥104 P 
(1vs2) 
P  
(1vs3vs4) 
Total Hip  
Baseline 
      
  BMA (cm2) 33.8±0.37 33.2±0.40 33.0±0.73 33.0±0.52 0.283 0.423 
  BMC (g) 29.0±0.56 30.8±0.91 30.2±1.46 30.8±1.27 0.087 0.338 
  T-score                -0.67±0.12 -0.14±0.19 -0.25±0.28 -0.10±0.28 0.014 0.075 
Final       
  BMA (cm2) 33.9±0.37 33.5±0.45 33.7±0.79 33.2±0.52 0.444 0.629 
  BMC (g) 29.3±0.57 31.1±0.97 31.1±1.55 30.8±1.39 0.078 0.286 
  T-score                -0.63±0.13 -0.13±0.19 -0.17±0.29 -0.13±0.28 0.021 0.103 
  T-score                -0.63±0.13 -0.13±0.19 -0.17±0.29 -0.13±0.28 0.019 0.114 Intertrochanter  
Baseline 
      
  BMA (cm2) 18.1±0.29 17.6±0.37 17.5±0.74 17.6±0.36 0.302 0.529 
  BMC (g) 18.4±0.40 19.7±0.67 19.2±1.17 19.8±0.86 0.070 0.285 
  T-score -0.51±0.12 0.13±0.17 -0.01±0.26 0.16±0.26 0.003 0.023† 
Final       
  BMA (cm2) 18.3±0.28 17.8±0.39 17.9±0.75 17.7±0.37 0.326 0.606 
  BMC (g) 18.7±0.41 20.0±0.71 20.0±1.19 19.9±0.98 0.080 0.283 
  T-score -0.4 ±0.12 0.14±0.17 0.10±0.27 0.12±0.25 0.004 0.034* 
Trochanter  
Baseline 
      
  BMA (cm2) 10.7±0.14 10.6±0.23 10.6±0.45 10.4±0.25 0.674 0.694 
  BMC (g) 6.91±0.15 7.13±0.26 7.19±0.42 6.96±0.36 0.449 0.779 
  T-score -0.55±0.12 -0.29±0.18 -0.30±0.24 -0.32±0.30 0.225 0.542 
Final       
  BMA (cm2) 10.7±0.15 10.7±0.24 10.8±0.41 10.5±0.33 0.995 0.889 
  BMC (g) 6.92±0.15 7.18±0.27 7.27±0.44 7.01±0.39 0.363 0.659 
  T-score -0.53±0.12 -0.33±0.18 -0.31±0.25 -0.39±0.31 0.359 0.698 
Data presented as mean ± SE. Non diabetic = non DM, all diabetic group = all DM, DM<10 = diagnosed diabetes <10 years, DM ≥10 = diagnosed 
diabetes ≥10 years. a Diabetes duration unknown in 4 participants. ANOVA showed a statistical difference across all three groups (ANOVA, 
p<0.05) with significant pairwise post-hoc tests denoted between: * non DM and DM<10, † non DM and DM≥10  
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Appendix B. DXA Measurements of the Lumbar Spine and Forearm at Baseline and Final Visit According to DM Status. 
Data presented as mean ± SE.  
Non diabetic = non DM, all diabetic group = all DM, DM<10 = diagnosed diabetes <10 years, DM ≥10 = diagnosed diabetes ≥10 years 
aDiabetes duration unknown in 4 participants.  
No statistical differences were found (ANOVA, p<0.05).  
 Non DM1 All DM2 DM<103 DM≥104 P 
(1vs2) 
P 
(1vs3vs4) Total Spine 
Baseline 
      
  BMA (cm2) 58.1±0.51 57.1±0.97 57.2±1.46 57.3±1.52 0.287 0.687 
  BMC (g) 57.8±1.15 58.2±1.85 57.1±2.00 59.1±3.38 0.841 0.847 
  T-score -0.50±0.15 -0.29±0.20 -0.44±0.23 -0.22±0.34 0.377 0.686 
Final       
  BMA (cm2) 58.1±0.50 57.2±0.97 56.8±1.49 57.9±1.51 0.404 0.626 
  BMC (g) 57.5±1.15 58.8±1.82 56.9±2.14 60.7±3.28 0.545 0.457  
  T-score -0.55±0.14 -0.23±0.19 -0.43±0.25 -0.07±0.32 0.191 0.335 
Forearm 
Baseline 
      
  BMA (cm2) 23.5±0.22 24.1±0.34 23.9±0.51 24.4±0.52 0.138 0.257 
  BMC (g) 11.5±0.21 11.8±0.27 11.8±0.37 11.8±0.45 0.413 0.761 
  T-score -1.47±0.14 -1.44±0.18 -1.35±0.29 -1.58±0.25 0.918 0.849 
Final       
  BMA (cm2) 23.6±0.22 23.9±0.34 23.8±0.50 24.1±0.54 0.438 0.639 
  BMC (g) 11.4±0.21 11.7±0.28 11.7±0.37 11.7±0.47 0.475 0.778 
  T-score -1.57±0.14 -1.49±0.18 -1.36±0.29 -1.61±0.25 0.724 0.783 
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Appendix C. Consent Form. 
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Appendix D. Medical History Form.  
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Findings and Conclusions: DXA results revealed increased BMD in the hip regions of the 
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stratification of the diabetes group by duration supports the possibility of a 
biphasic effect evidenced by increasing BMD in the hip region the first 10 years 
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Additionally, mechanisms affecting bone metabolism in non DM models may not 
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